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ABSTRACT 
Women of African ancestry (AA) experience a greater burden from breast cancer 
and type 2 diabetes compared to women of European ancestry.  Some of the racial 
disparities observed for these diseases may be explained by AA-specific genetic risk 
variants.  The projects conducted here sought to discover risk variants in AA women for 
overall and subtype-specific breast cancer and for type 2 diabetes using pathway- and 
gene-based analytic approaches. 
Project 1 evaluated 170,812 mostly rare variants across the exome in 3629 breast 
cancer cases (1093 estrogen receptor negative (ER-), 1968 ER+, 568 ER unknown) and 
4658 controls from the African American Breast Cancer Epidemiology and Risk 
(AMBER) Consortium.  Gene-based analyses found ER- associations with PDE4D 
(previously identified in GWAS) and FBXL22 (novel), based on very small counts at 
extremely rare SNPs.   
Project 2 evaluated common SNPs in 308 genes in hormone pathways using 3663 
breast cancer cases (1098 ER-, 1983 ER+, 582 ER unknown) and 4687 controls from 
AMBER.  Gene-based and single SNP analyses identified eight genes (CALM2, CETP, 
NR0B1, IGF2R, CYP1B1, PGR, MAPK3, and MAP3K1) that contained common variants 
	
	
	 viii 
associated with overall or subtype-specific breast cancer after gene-level correction for 
multiple testing. 
Project 3 evaluated common SNPs in 69 genes involved in the Wnt pathway using 
2632 type 2 diabetes cases and 2596 controls from the Black Women’s Health Study.  
Gene-based and single SNP analyses were run, and an association was observed between 
the PSMD2 gene region and type 2 diabetes.  Association data on a subset of the top 
PSMD2 SNPs were available from a large, independent AA sample; associations were in 
the same direction, but weak and not statistically significant.  We also identified a 
TCF7L2 SNP that may represent a novel, independent association signal seen only in AA 
populations. 
Many of the SNPs identified in the present research are more common in AA 
populations, possibly explaining their lack of discovery by European ancestry genome-
wide association studies.  Replication of the associations we observed using independent 
AA samples is necessary.  Future studies should consider the entire gene regions 
identified in our research rather than focusing solely on the specific variants highlighted. 
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INTRODUCTION 
Women of African ancestry (AA) experience a greater burden from breast cancer 
compared to women of European ancestry.  Although incidence of breast cancer has 
historically been higher in white women, a recent report from the Surveillance, 
Epidemiology, and End Results (SEER) program of the National Cancer Institute showed 
an increase in breast cancer incidence among AA women from 2008 to 2012, during 
which time the incidence rate for white women remained relatively stable.  This resulted 
in a convergence of the breast cancer incidence rates for AA and white women in 2012 
(1).  At the same time as the incidence rates are converging, AA women continue to 
experience higher mortality from breast cancer.  Based on SEER data, there were 31.0 vs. 
21.9 (age-adjusted) breast cancer deaths per 100,000 U.S. black vs. non-Hispanic white 
women per year from 2008 to 2012 (1). 
The higher mortality from breast cancer experienced by AA women is likely due 
in part to their more aggressive disease profile.  AA women have a younger mean age at 
diagnosis compared to women of European ancestry, with this difference being small but 
statistically significant (60.3 compared to 61.1 years, based on 2010 SEER data, and 
adjusted for the overall younger age distribution of U.S. blacks) (2).  Likewise, a higher 
proportion of AA women are diagnosed before age 50 (3).  Multiple studies and data 
sources have shown that AA women are more likely to be diagnosed with estrogen 
receptor (ER) negative (4–6), triple-negative (1,6,7), and basal-like breast cancers (8), 
which carry a poor prognosis.  For example, in the 2012 SEER data, AA women had 
twice the proportion of triple-negative breast cancers compared to non-Hispanic whites 
	
	
	
2 
(22% vs. 11%) (1).  In addition, AA women are more likely to present with breast 
cancers that have progressed beyond Stage I and are classified as regional or metastatic 
(4,5,7,9).  Furthermore, NIS data showed that AA women with a primary diagnosis of 
breast cancer are more likely to present with comorbidities than white women (adjusted 
odds ratio = 1.58, p < 0.001) (9).   
While the higher breast cancer mortality experienced by AA women may in part 
be due to their aggressive disease profile, studies have reported higher risks of breast 
cancer death and lower survival rates even after accounting for tumor characteristics such 
as stage and hormone receptor status (1,3,5).  Therefore, additional factors likely 
contribute to the racial disparities seen in breast cancer outcomes.  Socioeconomic status 
(SES) and access to health care may play a role; however, studies controlling for factors 
related to SES and health care access have still shown a higher risk of breast cancer death 
in AA vs. white women (4,5).  Thus, it is likely that there are true biological differences 
impacting these racial disparities. 
 In addition to the disparities observed for breast cancer, AA women also 
experience a greater burden from type 2 diabetes compared to women of European 
ancestry.  While the prevalence of this disease has risen greatly over the past several 
decades across multiple racial groups, African Americans have experienced a 
disproportionate increase in the number of cases.  Evidence of this disparity comes from 
the National Health and Nutrition Examination Surveys (NHANES), which showed a 
greater rise in the prevalence of type 2 diabetes from NHANES I (1971-1975) to 
NHANES 1999-2004 among African Americans (206.7% increase) vs. whites (169.0% 
	
	
	
3 
increase) (10).  In line with these observed trends in prevalence, the incidence of type 2 
diabetes in African American women has been reported to be more than twice that in 
white women (11).  Furthermore, African Americans with diabetes have shown poorer 
glycemic control (12) and an increased risk of diabetic complications and mortality (13) 
compared to whites. 
Racial disparities in factors predisposing to type 2 diabetes have also been 
detailed.  The prevalence of obesity is higher in AA vs. white women, and AA women 
have lower daily energy expenditure including less physical activity and comparatively 
smaller volumes of metabolically active organs (14).  In addition, nondiabetic African 
American women have higher fasting insulin levels compared to whites, and this has 
been shown for both obese and nonobese women (15).  Greater insulin resistance has also 
been observed in nondiabetic African Americans vs. whites (16).  Despite these racial 
differences in factors predisposing to diabetes, it has been reported that more than half of 
the excess risk of type 2 diabetes in AA women remains after adjustment for known risk 
factors including body mass index (BMI) (11).  Thus, additional elements must be at play 
in producing the racial disparities seen. 
 Genetic differences between AA and white women may explain some of the racial 
disparities in breast cancer mortality and type 2 diabetes incidence.  Risk alleles that are 
more common in AA populations may drive the occurrence of more aggressive breast 
tumors and may also lead to higher breast cancer mortality through biological 
mechanisms that are independent of commonly assessed tumor characteristics.  Likewise, 
type 2 diabetes susceptibility alleles that are more common in AA populations may lead 
	
	
	
4 
to higher incidence through known predisposing factors such as BMI and insulin 
resistance, or through other biological mechanisms that are independent of commonly 
measured diabetes risk factors.   
Most previously reported genetic risk loci for breast cancer and type 2 diabetes 
have been discovered in genome-wide association studies (GWAS) of European or Asian 
ancestry populations (17–23), and the majority of these associations have failed to reach 
statistical significance in studies of AA subjects (24–40).  This further suggests the 
presence of risk variants specific to AA individuals and emphasizes the need for more 
genetic research in this understudied but disproportionately affected population.  Another 
reason for conducting genetic association studies in AA populations is their greater 
genetic variability compared to European or Asian ancestry populations.  Lower levels of 
linkage disequilibrium (LD) exist in AA populations (i.e. genetic markers are less 
correlated with each other on average, and these correlations span shorter stretches of the 
genome); therefore, genetic variants associated with disease in AA studies are more 
likely to be located closer to the underlying causal variants (41,42). 
 Given the disease disparities and research rationale described above for AA 
populations, the projects conducted here sought to discover risk variants for overall and 
subtype-specific breast cancer (Projects 1 and 2) and for type 2 diabetes (Project 3) in 
women of African ancestry from the African American Breast Cancer Epidemiology and 
Risk (AMBER) Consortium Study (Projects 1 and 2) and the Black Women’s Health 
Study (BWHS) (Project 3).  Association analyses were carried out using genotyped and 
imputed data generated from large-scale arrays, which included selected custom content 
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in biological pathways of interest.  Pathway- and gene-based analytic approaches were 
utilized in an attempt to identify important pathways and genes with multiple risk 
variants that might otherwise be missed in a SNP-based approach.  The projects were 
bolstered by use of the largest AA sample to date for studying breast cancer genetics 
(~3600 cases and 4700 controls) and by a respectable AA sample size for type 2 diabetes 
(~2600 cases and 2600 controls). 
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PROJECT 1 
 
An Exome-Wide Analysis of Low Frequency and Rare Variants in Relation to  
Risk of Breast Cancer in African American Women: the AMBER Consortium 
 
(Carcinogenesis 2016; 37(9): 870-877, with permission of Oxford University Press) 
 
 
 
ABSTRACT 
A large percentage of breast cancer heritability remains unaccounted for, and 
most of the known susceptibility loci have been established in European and Asian 
populations.  Rare variants may contribute to the unexplained heritability of this disease, 
including in women of African ancestry (AA).  We conducted an exome-wide analysis of 
rare variants in relation to risk of overall and subtype-specific breast cancer in the African 
American Breast Cancer Epidemiology and Risk (AMBER) Consortium, which includes 
data from four large studies of AA women.  Genotyping on the Illumina Human Exome 
Beadchip yielded data for 170,812 SNPs and 8287 subjects: 3629 cases (1093 estrogen 
receptor negative (ER-), 1968 ER+, 568 ER unknown) and 4658 controls, the largest 
exome chip study to date for AA breast cancer.  Pooled gene-based association analyses 
were performed using the unified optimal sequence kernel association test (SKAT-O) for 
variants with minor allele frequency (MAF) ≤ 5%.  In addition, each variant with MAF 
>0.5% was tested for association using logistic regression.  There were no significant 
associations with overall breast cancer.  However, a novel gene, FBXL22 (gene-based p = 
8.2 x 10-6), and a gene previously identified in GWAS of European ancestry populations, 
PDE4D (gene-based p = 1.2 x 10-6), were significantly associated with ER- breast cancer 
after correction for multiple testing.  Cases with the associated rare variants were also 
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negative for progesterone and human epidermal growth factor receptors – thus, triple-
negative cancer.  Replication is required to confirm these gene-level associations, which 
are based on very small counts at extremely rare SNPs. 
 
INTRODUCTION 
 Genome-wide association studies (GWAS) have identified more than 90 genetic 
loci associated with breast cancer (1,2).  Per-allele odds ratios have been modest (most 
<1.2), as is typical for GWAS findings.  These low-penetrance loci, together with 
previously discovered high- and moderate-penetrance genes, fail to explain the majority 
of the genetic contribution to the disease (1–4).  Most GWAS-based associations have 
been established in European or Asian populations, and the majority of these associations 
have failed to reach statistical significance in studies of African ancestry (AA) women 
(5–15).  While larger AA sample sizes and accounting for differences in linkage 
disequilibrium (LD) across ethnicities would likely result in more successful replications, 
the European-discovered risk variants may also explain less of the genetic contribution to 
breast cancer in AA women. 
While some of the unexplained breast cancer heritability in AA women may be 
due to unidentified common susceptibility SNPs in this population, another portion may 
be explained by less common (1-5%) and rare variants (< 1%).  These lower frequency 
variants represent a large proportion of all human genetic variation but are poorly 
captured by most GWAS arrays (16).  There are a growing number of examples of rare 
variants associated with complex disease, with findings for autism, schizophrenia, 
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inflammatory bowel disease, and diabetes (17).  In addition to the already established 
high- and moderate-penetrance genes for breast cancer (3,4,18), novel low frequency risk 
variants for cancers including prostate (19) and ovarian (20,21) have also been reported.  
Still, it remains unclear how much rare variants contribute to the heritability of breast 
cancer and other complex diseases. 
In recent years the development of exome-wide arrays has allowed for the 
relatively inexpensive assessment of known rare exonic variants.  Current exome arrays 
include >200,000 coding variants and were developed on the basis of whole exome 
sequencing data from ~12,000 individuals.  Most of those sequenced were of European 
ancestry, but a small number of AAs and other ethnicities were included as well (16,22).   
A case-control study nested in the Multiethnic Cohort (MEC) used the Illumina 
exome chip to investigate the role of rare exonic variation in the etiology of breast cancer 
(16).  Single SNP analyses were conducted, as well as gene-based testing of the burden of 
rare alleles.  Only one significant association was found, for splice-site SNP rs145889899 
in the LDLRAD1 gene.  This variant was only seen in AAs (with a frequency of 0.65% in 
AA controls) and had an odds ratio of 3.74.  While no additional findings were 
significant, there was low power to detect genotype relative risks ≤ 2 in the AA 
participants due to the modest number of available AA cases (N = 591). 
 The present study combined the MEC exome chip data with exome chip data 
from three additional studies of breast cancer in AA women, forming the African 
American Breast Cancer Epidemiology and Risk (AMBER) Consortium, the largest 
exome wide analysis sample to date for AA breast cancer (3629 cases and 4658 controls).  
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We primarily used gene-based methods for association analysis, given the relatively low 
power and high multiple testing burden for single SNP analyses of rare variants (22,23).  
Gene-based testing has the potential to increase power when multiple SNPs in a given 
gene are associated (22). 
 
METHODS 
Study Population 
This investigation was conducted using data from the AMBER Consortium, a 
collaboration of four of the largest studies of breast cancer in AA women.  The AMBER 
Consortium has been described previously (24), and prior reports have detailed the 
individual studies: the Carolina Breast Cancer Study (CBCS) (25), the Women’s Circle 
of Health Study (WCHS) (26,27), the Black Women’s Health Study (BWHS) (28), and 
the Multiethnic Cohort (MEC) (29).  Institutional Review Board approval was obtained 
for each study, and all participants provided written informed consent. 
Briefly, the CBCS is a North Carolina population-based case-control study of 
women aged 20 to 74 years that began in 1993.  The North Carolina Central Cancer 
Registry’s rapid case ascertainment system was used for case identification, and controls 
were selected through 2001 using Division of Motor Vehicles lists (age <65 years) and 
Health Care Financing Administration lists (age ≥ 65).  Interviewers collected 
questionnaire data and samples for DNA analysis in home visits. 
The WCHS is a multi-site case-control study in New York City (NYC) (2002-
2008) and New Jersey (NJ) (2006-present).  Hospital-based ascertainment of cases aged 
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20 to 75 years was used in NYC, and controls were selected through random digit dialing 
(RDD).  Cases in NJ are identified by the NJ State Cancer Registry using rapid case 
ascertainment, and controls are identified through RDD and community-based efforts 
(27).  Risk factor data and samples for DNA analysis are obtained during in-person 
interviews. 
The BWHS is a prospective cohort study of 59,000 AA women from across the 
United States who enrolled by completing a postal health questionnaire in 1995.  The age 
range at baseline was 21–69 years.  Biennial follow-up questionnaires identify new cases 
of breast cancer, and these cases are confirmed by medical records or from state cancer 
registry data and the National Death Index.  Nearly 27,000 BWHS participants provided 
saliva samples for DNA analysis. 
The MEC is a prospective cohort study that began in 1993 with the enrollment of 
men and women aged 45–75 years from a range of ethnic groups in Hawaii and 
California.  Data are collected by mailed questionnaire at 5-year intervals, and breast 
cancer cases are confirmed through the Hawaii and California state cancer registries and 
the National Death Index.  Blood samples were collected from study participants for 
DNA analysis. 
Eligible cases for the present analyses were AA women with incident invasive 
breast cancer or ductal carcinoma in situ (DCIS).  For BWHS and MEC, controls were 
chosen from among women without breast cancer, and were frequency matched to cases 
on geographical region, sex, race, and 5-year age group.  Estrogen receptor (ER) status 
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for cases was determined using pathology data from hospital records or cancer registry 
records. 
 
Genotyping and QC 
Genotyping of DNA from participants in the BWHS, CBCS, and WCHS was 
performed by the Center for Inherited Disease Research (CIDR) using the Illumina 
Human Exome Beadchip v1.1.  This array includes >200,000 coding variants, as well as 
tag SNPs for GWAS hits, a grid of common variants, and ancestry informative markers 
(AIMs).  A description of the exome chip design is available from 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design.  CIDR used the GenTrain 
Version 1.0 calling algorithm in GenomeStudio version 2011.1, Genotyping Module 
1.9.4.  Manual review was conducted for all Y, XY pseudoautosomal, and mitochondrial 
SNPs.  Autosomal and X chromosome SNPs were also manually reviewed if a rare 
heterozygous cluster may have been missed by the GenCall algorithm and if the zCall 
algorithm (30) identified four or more possible new heterozygous points. 
A total of 246,519 SNPs were genotyped, and 231,705 SNPs remained after 
excluding variants that failed technical filters imposed by CIDR, or QC filters 
recommended by the University of Washington.  Briefly, genotypes with a GenCall (GC) 
score <0.15 were classified as missing, and SNPs were removed if they had poor cluster 
properties (ex. cluster separation <0.2 or <0.3 depending on allele frequency), call rates 
<0.98, Hardy-Weinberg Equilibrium p <1x10-4, >1 Mendelian error in trios from HapMap 
(31), or >2 discordant calls in duplicate samples.  Mitochondrial and Y chromosome 
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SNPs were also removed.  Genotypes were attempted for 6936 participants from the 
BWHS, CBCS, and WCHS, and were completed with call rate >98% for 6828 
participants, which included 3130 cases (963 estrogen receptor negative (ER-), 1674 
ER+, 493 ER unknown) and 3698 controls. 
Genetic data from 499 cases (130 ER-, 294 ER+, 75 ER unknown) and 960 
controls in the MEC were available from genotyping on a previous version of the exome 
chip (16) which contained >99% of the high quality variants from v1.1.  Genotypes from 
MEC were combined with the data from the other AMBER studies into a data set 
containing 245,571 SNPs.  Greater than 66,000 SNPs were monomorphic in the 
combined set and were omitted from analyses, as were SNPs with high quality data from 
only one of the two exome chips and SNPs with any discordant genotypes across the two 
chips for 30 MEC participants who were included on both.  The final data set for analysis 
included 170,812 SNPs and 8287 participants: 3629 cases (1093 ER-, 1968 ER+, 568 ER 
unknown) and 4658 controls.   
We used the CHARGE (Cohorts for Heart and Aging Research in Genomic 
Epidemiology) Consortium’s annotation of exome chip variants (version 6, 11/7/14) 
downloaded from http://www.chargeconsortium.com/main/exomechip (32).  This 
annotation was performed with dbNSFP version 2.6 (33,34).   
We used the smartpca program in the EIGENSOFT package (35) to conduct a 
principal components analysis (PCA) based on ~42,000 common SNPs, most of which 
were custom content additions to the exome chip for use in other AMBER projects.  In a 
separate analysis, PLINK version 1.07 (36) was used to estimate identity by descent in 
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participant pairs, and identified 130 sets of relatives across and within the individual 
studies, consisting of 270 individuals.  These 270 individuals were flagged, as were 35 
outlying individuals from the PCA, so that sensitivity analyses could be performed.  
Genotype principal components were tested for association with case status after 
controlling for the study covariates: study, DNA source (blood, saliva[Oragene], 
saliva[mouthwash]), and the matching variables.  While no principal components were 
strongly associated in the multivariable model, we included terms for principal 
components with p <0.1 in our analyses. 
 
Association Analysis 
Gene-based association analyses for overall, ER+, and ER- breast cancer were 
conducted using the unified optimal sequence kernel association test (SKAT-O) (37), as 
implemented in the R package seqMeta (38).  As a linear combination of the burden and 
SKAT (39) tests, SKAT-O achieves robust power whether a given gene has a high 
proportion of causal variants exerting effects in the same direction, or instead has many 
noncausal variants or variants exerting effects in opposite directions (22).  We used the 
default SKAT-O option in the seqMeta package that considers rho = 1 (burden) and rho = 
0 (SKAT) tests and selects the optimal of the two tests.  Depending on which test is 
chosen, SKAT-O models the phenotype vs. a weighted aggregation of either the variants 
(burden test) or the variant score test statistics (SKAT) to produce a gene-level p-value 
that indicates the degree of enrichment of rare variant associations in that gene (37).  We 
included variants with minor allele frequency (MAF) ≤ 5%, and used the beta distribution 
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weights proposed by Wu et al. (39), which upweight rarer variants, for both tests.  We 
used a Bonferroni correction based on the number of genes evaluated to assess the 
significance of the gene-based test results.   
We performed separate gene-based analyses for three sets of exonic variants: 1) 
“NS_strict” variants (based on Purcell et al. (40)): stopgain, stoploss, frameshift, or 
predicted damaging by all five of the following algorithms: SIFT (41), mutationTaster 
category [A or D] (42), LRT (43), PolyPhen_HDIV (44), and PolyPhen_HVAR (44), 2) 
“NS_broad” variants (Purcell et al. (40)): “NS_strict” variants plus those variants that are 
predicted damaging by at least one of the five algorithms, and 3) All nonsynonymous 
variants (“NS_all”): “NS_broad” variants plus all other missense and splice variants.  
Testing of these three sets of variants gave us more flexibility to find the best set of SNPs 
for gene-based analysis (ideally a set including most or all truly associated SNPs, but 
few, if any, unassociated SNPs). 
Single SNP association analyses were conducted using logistic regression as 
implemented in PLINK version 1.07.  These analyses were restricted to variants with 
MAF >0.5% in order to avoid performing a large number of underpowered tests.  We 
used a Bonferroni adjustment for the effective number of independent tests, applying the 
method of Gao et al. (45), to assess the significance of the single SNP results.  
Both gene-based and single SNP analyses were adjusted for study, age, 
geographic region, DNA source, and genotype principal components 5, 6, and 8 in a 
pooled analysis that combined individual level data across the four studies in AMBER.  
This approach was preferred over meta-analysis given prior evidence that pooled analysis 
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is more powerful for gene-based testing of rare variants under conditions where pooling 
is appropriate (46). 
 
RESULTS 
The present analyses included 3629 breast cancer cases (1093 ER-, 1968 ER+, 
568 ER unknown) and 4658 controls.  Table 1.1 shows the distribution of ER subtypes 
and age at diagnosis for the cases by study site. 
There were 184,100 annotation records for the 170,812 SNPs that passed QC 
filters: some SNPs mapped to more than one gene, and these multiple mappings were 
maintained for the gene-based analyses we performed.  More than 80% of the SNP 
records were annotated as nonsynonymous, including missense, stopgain, stoploss, 
frameshift, and splicing variants (see Supplementary Table 1.S1 for the full distribution 
of roles for the final SNP set).  Over 80% of the SNPs had MAF <5% in AMBER, over 
70% had MAF <1%, and nearly half of the SNPs had MAF <0.1%.  QQ plots for the 
gene-based and single SNP association analyses we performed are shown in 
Supplementary Figure 1.S1.  As is common for SKAT analyses of binary traits, there was 
inflation in the gene-based test results (47,48). 
The number of gene-based tests conducted and the resulting alpha levels for 
significance are listed in Table 1.2 by outcome and SNP group.  As the SNP functional 
group became more strict, fewer tests were conducted because fewer genes contained at 
least two SNPs in the given group.  Fewer gene-based tests were conducted for the ER+ 
and ER- analyses compared to overall breast cancer because these subtype analyses had 
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smaller sample sizes, which resulted in more monomorphic SNPs that were excluded. 
Table 1.3 shows the five most significant genes for each SKAT-O run (see 
Supplementary Table 1.S2 for the top 50 genes for each set of variants).  For overall and 
ER+ breast cancer, RTN4RL1 was the most significant gene for both the “NS_all” and 
“NS_broad” SNP sets, with nominal p-values ranging from 1.8 x 10-5 to 1.9 x 10-4.  These 
results were based on 6-10 SNPs that were used in burden tests (the SKAT-O method 
selected rho = 1 as optimal in these instances).  For the “NS_strict” variants, the most 
significant genes for overall and ER+ breast cancer were IQCA1 (p = 4.6 x 10-4) and 
FSCN3 (p = 2.3 x 10-4), respectively.  None of the top results for overall or ER+ breast 
cancer survived a multiple testing correction based on the number of genes evaluated. 
The most significant genes for ER- breast cancer were PDE4D (p = 1.2 x 10-6 
using either the “NS_all” or “NS_broad” SNP sets) and FBXL22 (p = 8.2 x 10-6 using the 
“NS_strict” SNP set), and these survived a correction for multiple testing.  The PDE4D 
and FBXL22 results were each based on burden testing (rho = 1) of two SNPs with a 
cumulative MAF ~0.02%.  Details of the four SNPs contributing to these significant test 
results are shown in Table 1.4.  All of the contributing SNPs are nonsynonymous coding 
SNPs for multiple isoforms of PDE4D or FBXL22.  These SNPs had good genotyping 
cluster properties (Supplementary Figure 1.S2) and 100% genotyping pass rates in the 
present study.  Each SNP had an MAF ~0.01% in the AMBER analysis of ER- cases and 
controls, due to the presence of one rare allele in one invasive ER- case.  The rare allele 
carriers were four independent participants (one for each SNP) with varying ages at 
diagnosis and percentages of African ancestry (Table 1.4).  All four of these women had 
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triple-negative breast cancer (tumors negative for estrogen receptors, progesterone 
receptors and human epidermal growth factor receptor 2).  Among all 1093 ER- cases, 
599 had been classified as triple negative based on available data on all three molecular 
markers.  The four SNPs of interest are monomorphic in AAs from the 1000 Genomes 
Project (49) Phase 3 and the NHLBI ESP (National Heart, Lung, and Blood Institute 
Exome Sequencing Project) (50).  These same projects report very low allele frequencies 
(≤ 0.2%) for these SNPs in European ancestry populations (Table 1.4). 
Sensitivity analyses were run for the PDE4D and FBXL22 genes vs. ER- breast 
cancer, excluding first-degree and second-degree relatives identified via the genotypes, as 
well as PCA outliers who clustered with HapMap 3 Europeans, Mexicans, or Asians.  
Results became more significant with these exclusions (PDE4D p = 9.9 x 10-7; FBXL22 p 
= 7.4 x 10-6).  
 Single SNP association analyses were performed for the 58,776 SNPs with MAF 
>0.5%.  The correlation among these SNPs yielded the equivalent of 50,245 independent 
tests (45); therefore, the threshold for significance was set at 9.95 x 10-7.  SNP rs8100241, 
a previously reported risk marker at the ER- / triple-negative GWAS locus on 
chromosome 19p13.11 (12,51–55), met this study-wide threshold for ER- disease (p = 
1.7 x 10-7).  The A allele at rs8100241 had a frequency of 40% in the present study and 
was associated with a decreased risk of ER- breast cancer (OR 0.75, 95% CI 0.68, 0.84).  
No other individual SNPs reached statistical significance (Supplementary Table 1.S3), 
including the LDLRAD1 SNP rs145889899 (p = 0.17), for which an association had been 
reported in the MEC exome chip study (16).   
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DISCUSSION 
In these analyses, we observed significant associations between the PDE4D and 
FBXL22 genes and ER- breast cancer in a relatively large sample of AA women, using 
gene-based testing of rare exonic variants.  Two nonsynonymous coding SNPs in each of 
these genes were responsible for their significant associations.  The minor allele at each 
of these four SNPs was present in one invasive ER- case each (a different case subject for 
each of the four SNPs).  These four cases were all triple-negative breast cancers.  The 
four SNPs of interest from these two genes were absent in the AMBER controls.  This is 
consistent with their reported monomorphism in AA samples from the 1000 Genomes 
Project and the NHLBI ESP.   
Although the association we report for the PDE4D gene is with ER- (and triple-
negative) breast cancer, one of the two rare SNPs contributing to this association 
(rs201360779) was also seen in one invasive ER+ case.  Thus, this gene may affect the 
risk of both ER subtypes.  The two contributing PDE4D SNPs in our study were 
predicted to be damaging by mutationTaster (42), although SIFT (41) predicted that these 
mutations would be tolerated.  The PolyPhen HDIV and HVAR models (44) predicted 
damaging results from rs200725508, but these algorithms predicted benign results for 
rs201360779 (with the exception of the HDIV prediction of “possibly damaging” for this 
SNP for one PDE4D isoform). 
The 2013 GWAS meta-analysis by Michailidou and colleagues (1) reported a 
breast cancer association with SNP rs1353747, which is located in an intron of PDE4D.  
In that study, the minor G allele at this common SNP showed weak protective 
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associations for both ER+ (OR = 0.93) and ER- (OR = 0.92) disease.  In the current 
study, rs1353747 showed slightly stronger effects but in the opposite direction (ER+ OR 
= 1.13; ER- OR = 1.29), and these results did not reach statistical significance given the 
smaller sample size compared to Michailidou et al. and the lower frequency of this 
variant in African vs. European populations (1% vs. 8% based on 1000 Genomes). 
PDE4D is located on chromosome 5q11.2-12.1 and encodes phosphodiesterase 
subtype 4D, a member of the PDE4 family of phosphodiesterases, which multiple tumor 
cell types express as major regulators of cAMP degradation (56).  PDE4D may function 
as a tumor-promoting factor by causing lower cAMP concentrations, which have been 
linked to increased survival and proliferation of cancer cells.  This oncogenic role is 
supported by experiments showing that inhibition of PDE4D causes apoptosis and growth 
retardation in multiple types of cancer cells, including breast, but not in nonmalignant 
epithelial cells (56).   
Lin et al. (56) reported PDE4D homozygous deletions in 198 of 5569 (3.6%) 
primary tumors from The Cancer Genome Atlas (TCGA) projects and TumorScape (57), 
with most being internal microdeletions.  They also found microdeletions in established 
cancer cell lines including breast.  These microdeletions were associated with increased 
expression of the protein, and they affected upstream conserved regions 1 (UCR1) and 2 
(UCR2) of the gene.  UCR1 and UCR2 inhibit PDE4D activity, likely by forming 
complexes with the PDE4D catalytic domain before cAMP enters the site.  Lin et al. 
showed that a short isoform of PDE4D with no functional UCR1 or UCR2 promoted 
cancer cell growth, while a long isoform that contained both UCR1 and UCR2 did not.  
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In the present study, the two rare missense mutations contributing to the PDE4D gene-
level association were located upstream of UCR1 and UCR2 and were risk variants (not 
protective).  It could be hypothesized that these variants act by inducing a change in 
protein structure that disrupts the interaction of the UCRs with the catalytic domain of 
PDE4D, thereby increasing protein activity. 
 FBXL22 has not previously been associated with breast cancer.  This gene is 
located on chromosome 15q22.31 and encodes F-box and leucine-rich repeat protein 22.  
This F-box protein, a ubiquitin ligase component, has been shown to promote the 
degradation of sarcomeric proteins, and is critical for maintaining cardiac contractility in 
vivo (58).  It is unclear what biological mechanism might link FBXL22 to breast cancer 
development.  Nevertheless, the two rare SNPs contributing to the FBXL22 / ER- 
association in this study met strict criteria for variant functionality: these nonsynonymous 
SNPs were predicted to be damaging by five different algorithms (41–44). 
Single SNP analyses confirmed an ER- association for the GWAS locus on 
chromosome 19p13.11 (12,51–55).  The associated SNP in the present study was the 
common missense variant rs8100241 in the ANKLE1 gene.  This SNP has shown 
significant associations with overall (51), ER- (54), and triple-negative (52) breast cancer 
in prior studies of mostly European ancestry subjects.  These studies reported odds ratios 
ranging from 0.84 to 0.88 for the A allele at this SNP, as compared with the odds ratio of 
0.75 reported in the present analysis for ER- breast cancer.  It should be noted, however, 
that the large GAME-ON meta-analysis (http://gameon.dfci.harvard.edu) reported weaker 
effect estimates for rs8100241: the odds ratio reported for overall breast cancer was 0.95 
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(95% CI 0.92, 0.99; p = 0.017), and the odds ratio for ER- breast cancer was 0.94 (95% 
CI 0.83, 1.07; p = 0.36). 
Although the present study sample is the largest exome wide analysis sample to 
date for AA breast cancer, this analysis was underpowered to detect per-allele odds ratios 
<1.5, except when cumulative risk allele frequencies per gene approached or exceeded 
5%.  Further power limitations existed for analyses by ER status.  
The significant gene-level findings reported here are based on four SNP variants 
that appear only once each in the AMBER sample of ER- cases and controls.  Given 
these very small counts and the inflation seen in the gene-based test statistics, our results 
should be interpreted with caution.  A simple Fisher’s exact test for the presence of a rare 
allele in PDE4D vs. ER- case / control status yields a p-value of 0.036, as does the same 
test for FBXL22.  Fisher’s exact test is conservative and does not upweight rarer variants 
or account for covariates; however, the modest p-value from this test emphasizes the need 
for replication to verify associations between these genes and ER- breast cancer. 
This is not to say that the rare variant calls for the four SNPs of interest are 
questionable.  There is good reason to believe that these calls were accurate in our study.  
These SNPs are known rare variants that the exome chip was designed to capture.  Each 
SNP was seen in two or more studies that contributed sequence data for development of 
the exome chip: the minor allele at rs201360779 was seen 29 times across the ~12,000 
sequenced individuals, the minor allele at rs149590841 was seen seven times, and the 
minor alleles for the other two SNPs were each seen three times 
(ftp://share.sph.umich.edu/exomeChip/ProposedContent/codingContent/).  In AMBER, 
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all four SNPs showed high quality genotype clusters and clear separation of the 
heterozygous calls from the remainder of the genotypes.  In addition, SNP rs201360779 
was not a true singleton in AMBER, having also been seen in one ER+ case. 
The exome chip used here has inherent limitations.  First and most obvious, this 
array-based method includes only selected rare variants and is therefore not as exhaustive 
as exome sequencing in capturing rare exonic variants.  Second, this chip does not 
attempt to assay rare variation in noncoding regions.  Third, the chip was designed using 
exome sequencing data from mostly European samples.  Therefore, rare variants in non-
Europeans are not as well captured, and our data set may have lacked information on 
some important rare SNPs in AA populations (22).   
Another potential limitation of our study is a current limitation of the field: the 
use of traditional methods such as PCA (or linear mixed models) to adjust for population 
stratification in rare variant association studies.  These methods may not adequately 
control for population structure in some rare variant analysis settings; thus, the 
development of new methods for this purpose is an area of active research (23). 
We should also acknowledge that while our multiple testing correction adjusted 
for the number of genes analyzed, there were additional levels of testing that were not 
included in this correction.  Multiple outcomes (overall, ER+, ER- breast cancer) and 
SNP functional groups (NS_all, NS_broad, NS_strict) were also analyzed.  We did not 
correct for the multiple breast cancer outcomes because there was considerable overlap 
among the groups of patients analyzed for overall, ER+, and ER- breast cancer, and we 
considered these to be tests of related hypotheses.  There was also a high amount of 
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interdependence among the three SNP functional groups, which would render a 
Bonferroni correction overly conservative.  Nevertheless, implementing an adjustment 
for all of the ER- gene-based tests conducted across the three SNP functional groups 
results in a corrected p-value of 0.035 for PDE4D, although the corrected p-value for 
FBXL22 becomes non-significant (0.240). 
In summary, an exome-wide gene-based analysis of rare variants found 
significant associations between the PDE4D and FBXL22 genes and ER- breast cancer in 
a collaborative study of AA women.  The previous GWAS finding of a breast cancer risk 
marker in the PDE4D gene supports the idea that rare variants in this region in particular 
might affect breast cancer risk.  Replication is needed to confirm the gene-level 
associations reported here, which are based on very small counts at extremely rare 
variants. 
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Table 1.1:  Characteristics of participants in the AMBER Consortium by study site. 
 BWHS CBCS WCHS MEC ALL AMBER 
Controls 2249 615 834 960 4658 
      
Cases 901 1408 821 499 3629 
     ER+ 498 741 435 294 1968 
     ER- 233 565 165 130 1093 
     ER unknown 170 102 221 75 568 
      
Age at    
diagnosis      
        <40 47 204 85 0 336 
        40-49 262 459 215 9 945 
        50-59 302 381 292 108 1083 
        60-69 204 267 173 165 809 
        ≥ 70 86 97 56 217 456 
Abbreviations: ER, estrogen receptor; BWHS, Black Women’s Health Study; CBCS, Carolina 
Breast Cancer Study; WCHS, Women’s Circle of Health Study; MEC, Multi-Ethnic Cohort; 
AMBER, African American Breast Cancer Epidemiology and Risk. 
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Table 1.2:  Number of gene-based tests conducted and corresponding significance 
criteria. 
Analysis Number of genes tested Alpha level for significance 
Overall breast cancer   
     “NS_all” SNPsa 14,652 3.4 x 10-6 
     “NS_broad” SNPsb 12,515 4.0 x 10-6 
     “NS_strict” SNPsc 3128 1.6 x 10-5 
   
ER+ breast cancer   
     “NS_all” SNPs 14,515 3.4 x 10-6 
     “NS_broad” SNPs 12,316 4.1 x 10-6 
     “NS_strict” SNPs 2963 1.7 x 10-5 
   
ER- breast cancer   
     “NS_all” SNPs 14,399 3.5 x 10-6 
     “NS_broad” SNPs 12,184 4.1 x 10-6 
     “NS_strict” SNPs 2865 1.8 x 10-5 
   
a “NS_all” SNPs:  stopgain, stoploss, frameshift, missense, or splicing. 
b “NS_broad” SNPs:  stopgain, stoploss, frameshift, or predicted damaging by at least one of the 
following algorithms: SIFT, mutationTaster category [A or D], LRT, PolyPhen_HDIV, or 
PolyPhen_HVAR. 
c “NS_strict” SNPs:  stopgain, stoploss, frameshift, or predicted damaging by all five algorithms. 
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Table 1.3:  The most significant gene-based test results for each analysis. 
Gene Nominal  p-value 
Corrected  
p-valuea rho
b Cumulative MAF (%) 
Number of 
SNPs included 
in the test 
Overall breast cancer, “NS_all” SNPs 
RTN4RL1 1.3 x 10-4 1 1 4.31 10 
TPCN1 2.0 x 10-4 1 0 0.32 9 
RARA 2.3 x 10-4 1 1 2.42 2 
KIF3C 3.0 x 10-4 1 1 2.62 6 
OBSCN 4.4 x 10-4 1 0 75.88 146 
 
Overall breast cancer, “NS_broad” SNPs 
RTN4RL1 1.9 x 10-4 1 1 1.96 6 
RARA 2.3 x 10-4 1 1 2.42 2 
GPRASP1 3.0 x 10-4 1 0 5.35 5 
NCAPG2 3.3 x 10-4 1 0 2.91 9 
TMEM130 3.6 x 10-4 1 0 0.11 2 
 
Overall breast cancer, “NS_strict” SNPs 
IQCA1 4.6 x 10-4 1 0 3.09 3 
PDE4A 1.2 x 10-3 1 1 0.53 2 
ECT2L 2.0 x 10-3 1 0 1.33 2 
GCKR 2.5 x 10-3 1 1 0.21 4 
ACSF3 2.6 x 10-3 1 1 0.17 3 
 
ER+ breast cancer, “NS_all” SNPs 
RTN4RL1 1.8 x 10-5 0.25 1 4.37 10 
OR2W5 7.3 x 10-5 1 1 16.16 11 
CYSRT1 1.0 x 10-4 1 1 0.23 2 
RNF130 1.3 x 10-4 1 0 0.69 3 
GABPA 1.3 x 10-4 1 1 0.02 2 
 
ER+ breast cancer, “NS_broad” SNPs 
RTN4RL1 3.2 x 10-5 0.39 1 2.00 6 
RNF130 1.3 x 10-4 1 0 0.69 3 
GABPA 1.3 x 10-4 1 1 0.02 2 
OR5H15 3.5 x 10-4 1 1 0.05 2 
TCHP 3.9 x 10-4 1 1 4.35 11 
 
ER+ breast cancer, “NS_strict” SNPs 
FSCN3 2.3 x 10-4 0.67 1 0.06 3 
GUF1 7.0 x 10-4 1 0 0.22 3 
ZIM3 7.8 x 10-4 1 1 0.87 2 
TSC2 8.0 x 10-4 1 0 0.61 5 
TBPL2 9.1 x 10-4 1 0 0.09 2 
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Gene Nominal  p-value 
Corrected  
p-valuea rho
b Cumulative MAF (%) 
Number of 
SNPs included 
in the test 
ER- breast cancer, “NS_all” SNPs 
PDE4D 1.2 x 10-6 0.017 1 0.02 2 
PLEKHG5 2.2 x 10-5 0.31 1 9.36 18 
CCNDBP1 4.4 x 10-5 0.64 0 0.06 3 
DIMT1 5.8 x 10-5 0.84 0 0.03 2 
TEX12 1.6 x 10-4 1 0 0.20 2 
 
ER- breast cancer, “NS_broad” SNPs 
PDE4D 1.2 x 10-6 0.015 1 0.02 2 
LRRC8D 1.8 x 10-5 0.22 0 0.26 3 
CCNDBP1 4.4 x 10-5 0.54 0 0.06 3 
MRPS31 9.8 x 10-5 1 1 1.12 2 
NCR1 1.1 x 10-4 1 0 0.50 2 
 
ER- breast cancer, “NS_strict” SNPs 
FBXL22 8.2 x 10-6 0.023 1 0.02 2 
CCNDBP1 3.8 x 10-5 0.11 0 0.05 2 
SCARB1 9.6 x 10-5 0.28 1 0.02 2 
QRSL1 9.8 x 10-5 0.28 0 0.07 2 
MFGE8 1.1 x 10-4 0.31 0 0.05 3 
 
Abbreviations: MAF, minor allele frequency. 
Bold font indicates significant results. 
a Bonferroni correction for the number of genes tested. 
b The rho parameter indicates whether the SKAT test (rho = 0) or burden test (rho = 1) gave the 
smallest p-value. 
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Table 1.4:  SNPs contributing to significant gene-based tests for ER- breast cancer. 
SNP rsID Function Fail ratea 
MAF:  
analysis 
sample 
(%)b 
MAFs:  
1000G Phase 3 
MAFs:   
NHLBI ESP 
The 1 AMBER subject with 1 rare allele 
Disease 
status Study 
Age at 
diagnosis 
% 
African 
ancestryc 
Gene PDE4D 
exm456537 rs201360779 missense 0 0.01 
Monomorphic 
except in FIN  
(1%) 
Monomorphic in 
AAs; 
0.05% in EAs 
ER-, 
PR-, 
HER2- 
BWHS 45 68.6 
exm456565 rs200725508 missense 0 0.01 No data 
Monomorphic in 
AAs; 
0.03% in EAs 
ER-, 
PR-, 
HER2- 
WCHS 61 99.6 
 
Gene FBXL22 
exm1168070 rs201654150 missense 0 0.01 No data 
Monomorphic in 
AAs; 
0.02% in EAs 
ER-, 
PR-, 
HER2- 
BWHS 48 82.6 
exm1168081 rs149590841 missense 0 0.01 
Monomorphic 
except in ITU 
(0.5%) 
Monomorphic in 
AAs; 
0.10% in EAs 
ER-, 
PR-, 
HER2- 
BWHS 35 61.8 
 
Abbreviations: 1000G, 1000 Genomes; NHLBI ESP, National Heart, Lung, and Blood Institute Exome Sequencing Project; FIN, Finnish; ITU, Indian 
Telugu in the UK; AAs, African Americans; EAs, European Americans; ER-, estrogen receptor negative; PR-, progesterone receptor negative; HER2-, 
human epidermal growth factor receptor 2 negative. 
a Genotyping fail rate in the present study. 
b Minor allele frequency in the AMBER analytic sample of ER- cases and controls.  All 4 SNPs have an MAF ~0.01%, which corresponds to the 
presence of 1 rare allele in 1 subject. 
c Percent African vs. European ancestry as estimated by ADMIXMAP (59) using 2624 AIMs (ancestry informative markers). 
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Supplementary Table 1.S1:  Exome chip SNP roles. 
Role Number of SNP annotation records Percent of total 
missense 145,549 79.1 
intronic 11,030 6.0 
intergenic 7494 4.1 
synonymous 6204 3.4 
ncRNA intronic 4807 2.6 
stopgain 2527 1.4 
downstream 1269 0.7 
splicing 1119 0.6 
3’ UTR 938 0.5 
upstream 911 0.5 
exonic 887 0.5 
ncRNA exonic 826 0.4 
5’ UTR 306 0.2 
stoploss 148 < 0.1 
frameshift 81 < 0.1 
ncRNA splicing 4 < 0.1 
Abbreviations: ncRNA, non-coding RNA; UTR, untranslated region.  
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Supplementary Table 1.S2:  The 50 most significant gene-based test results for each 
analysis. 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
Overall breast cancer, “NS_all” SNPs 
RTN4RL1 1.3 x 10-4 1 4.31 10 
TPCN1 2.0 x 10-4 0 0.32 9 
RARA 2.3 x 10-4 1 2.42 2 
KIF3C 3.0 x 10-4 1 2.62 6 
OBSCN 4.4 x 10-4 0 75.88 146 
CCNB2 4.9 x 10-4 1 2.44 7 
FAM172A 5.1 x 10-4 1 0.38 3 
OR6C74 6.0 x 10-4 0 6.52 7 
TEX12 6.3 x 10-4 0 0.21 2 
PNMA1 8.2 x 10-4 0 4.25 3 
TICAM1 9.4 x 10-4 1 0.94 10 
BMP10 1.0 x 10-3 1 5.31 6 
TBC1D2B 1.2 x 10-3 1 2.00 8 
NLRP6 1.3 x 10-3 0 5.67 13 
C1orf50 1.3 x 10-3 0 4.79 4 
ST8SIA6 1.4 x 10-3 0 1.56 5 
TRIM41 1.4 x 10-3 0 3.47 9 
TTLL9 1.4 x 10-3 1 3.19 12 
PLSCR5 1.5 x 10-3 1 4.94 3 
TCHP 1.5 x 10-3 1 4.39 12 
PDE8A 1.5 x 10-3 1 1.94 8 
OARD1 1.5 x 10-3 1 0.07 4 
GCA 1.6 x 10-3 0 1.21 3 
SLC6A17 1.6 x 10-3 0 0.37 5 
SIX5 1.7 x 10-3 0 0.69 3 
OR2W5 1.7 x 10-3 1 16.17 12 
OR4F6 1.8 x 10-3 0 2.36 11 
METRNL 1.8 x 10-3 1 7.66 12 
COA4 2.0 x 10-3 1 0.96 4 
BGLAP 2.3 x 10-3 0 6.52 5 
ORAI3 2.4 x 10-3 1 0.05 3 
LYZ 2.4 x 10-3 1 2.37 4 
ZNF133 2.5 x 10-3 0 0.80 6 
AMIGO1 2.6 x 10-3 1 1.72 4 
BMP4 2.6 x 10-3 1 0.95 3 
NDUFA2 2.6 x 10-3 0 0.02 2 
STK11 2.7 x 10-3 0 0.48 3 
DCDC5 2.7 x 10-3 1 14.08 17 
GABPA 2.8 x 10-3 1 0.03 2 
KRTAP10-10 2.9 x 10-3 1 1.65 3 
TMEM63C 2.9 x 10-3 0 1.03 5 
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Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
TRIM11 3.0 x 10-3 1 0.96 3 
GPR50 3.0 x 10-3 1 0.30 3 
RRP36 3.0 x 10-3 1 2.15 6 
PPP1R3F 3.1 x 10-3 1 1.12 3 
THBS3 3.2 x 10-3 1 0.83 7 
OR5H15 3.3 x 10-3 1 0.07 4 
PDZD8 3.3 x 10-3 0 6.51 9 
RNF130 3.5 x 10-3 0 0.69 3 
DGCR2 3.5 x 10-3 0 0.45 8 
     
Overall breast cancer, “NS_broad” SNPs 
RTN4RL1 1.9 x 10-4 1 1.96 6 
RARA 2.3 x 10-4 1 2.42 2 
GPRASP1 3.0 x 10-4 0 5.35 5 
NCAPG2 3.3 x 10-4 0 2.91 9 
TMEM130 3.6 x 10-4 0 0.11 2 
MYO16 5.8 x 10-4 1 0.89 11 
OR6C74 6.0 x 10-4 0 6.52 7 
CCNB2 6.3 x 10-4 1 2.38 6 
KIF3C 7.9 x 10-4 1 2.53 4 
PNMA1 8.2 x 10-4 0 4.25 3 
PDZD8 8.6 x 10-4 1 1.58 4 
LYZ 1.0 x 10-3 0 1.35 2 
C1orf50 1.3 x 10-3 0 4.78 3 
ST8SIA6 1.3 x 10-3 0 0.83 3 
ATP2B4 1.4 x 10-3 1 0.68 13 
PLSCR5 1.5 x 10-3 1 4.94 3 
GCA 1.6 x 10-3 0 1.21 3 
THBS3 1.6 x 10-3 1 0.84 8 
SLC6A17 1.6 x 10-3 0 0.37 5 
OR4F6 1.6 x 10-3 0 2.09 8 
MDGA2 1.7 x 10-3 0 0.24 6 
TCHP 1.7 x 10-3 1 4.32 11 
EXD1 1.8 x 10-3 0 0.17 3 
IQGAP3 1.8 x 10-3 0 6.94 19 
OR5H15 1.8 x 10-3 1 0.06 3 
FANCM 1.9 x 10-3 1 2.64 23 
KCNQ3 2.2 x 10-3 0 1.21 5 
OBSCN 2.2 x 10-3 0 54.73 109 
LRRC8D 2.3 x 10-3 1 0.29 3 
ORAI3 2.4 x 10-3 1 0.05 3 
ALG12 2.5 x 10-3 1 5.63 7 
THAP7 2.5 x 10-3 1 0.06 2 
AMIGO1 2.6 x 10-3 1 1.72 4 
BMP4 2.6 x 10-3 1 0.95 3 
	
	
	
	
41 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
IQCA1 2.6 x 10-3 0 4.89 12 
STK11 2.7 x 10-3 0 0.48 3 
SIX5 2.7 x 10-3 0 0.34 2 
GABPA 2.8 x 10-3 1 0.03 2 
TTLL9 2.9 x 10-3 1 1.51 11 
SRP68 2.9 x 10-3 1 0.43 3 
ZNF138 2.9 x 10-3 1 0.31 3 
PDCD6IP 3.0 x 10-3 0 0.15 3 
LDLR 3.1 x 10-3 0 1.79 10 
TBPL2 3.1 x 10-3 1 0.10 3 
RNF130 3.5 x 10-3 0 0.69 3 
OMG 3.6 x 10-3 0 2.78 2 
DGCR2 3.6 x 10-3 0 0.44 7 
TNFAIP3 3.6 x 10-3 0 2.15 6 
FERMT2 3.7 x 10-3 1 0.16 5 
FRMD6 3.7 x 10-3 0 0.98 7 
     
Overall breast cancer, “NS_strict” SNPs 
IQCA1 4.6 x 10-4 0 3.09 3 
PDE4A 1.2 x 10-3 1 0.53 2 
ECT2L 2.0 x 10-3 0 1.33 2 
GCKR 2.5 x 10-3 1 0.21 4 
ACSF3 2.6 x 10-3 1 0.17 3 
AGER 2.7 x 10-3 0 0.25 2 
TRPM8 2.9 x 10-3 0 1.56 3 
CTC1 2.9 x 10-3 1 0.65 4 
GRK1 2.9 x 10-3 1 0.73 2 
POMT1 3.0 x 10-3 0 1.36 4 
GLOD5 3.2 x 10-3 0 0.35 2 
CUBN 3.2 x 10-3 0 0.49 6 
STK17A 4.3 x 10-3 0 0.21 2 
AFF4 4.4 x 10-3 1 0.27 2 
TDO2 5.2 x 10-3 1 0.91 2 
OR52B2 5.3 x 10-3 0 0.20 2 
ITIH6 5.3 x 10-3 1 0.05 2 
MRPS30 5.5 x 10-3 1 0.42 3 
NOX5 5.8 x 10-3 0 1.08 5 
GC 5.8 x 10-3 1 0.16 2 
PLA2R1 6.0 x 10-3 0 2.09 4 
PDHA2 6.7 x 10-3 0 4.90 6 
BBS9 6.7 x 10-3 0 0.89 4 
FUK 6.7 x 10-3 0 0.99 6 
FSCN3 7.0 x 10-3 1 0.05 3 
FBXL22 7.1 x 10-3 1 0.01 2 
COLEC10 7.3 x 10-3 1 0.02 2 
	
	
	
	
42 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
TSC2 7.7 x 10-3 0 0.63 5 
COL6A6 7.8 x 10-3 0 0.74 6 
FAM198B 8.9 x 10-3 1 0.54 5 
NRG2 9.3 x 10-3 1 0.08 3 
CDH19 9.5 x 10-3 0 0.43 2 
STAG3 0.010 1 0.10 2 
ZIM3 0.011 1 0.83 2 
DNAH14 0.011 1 5.00 4 
PARK2 0.011 1 1.12 5 
KIF13B 0.011 1 0.62 5 
ZSCAN29 0.012 0 0.05 2 
ACSM3 0.012 1 4.29 7 
B4GALNT3 0.012 1 0.56 6 
TTLL6 0.012 1 0.19 3 
CCDC158 0.013 1 0.03 3 
CC2D1A 0.013 0 1.07 5 
SPTBN5 0.013 1 0.07 4 
AFAP1L1 0.014 0 0.56 4 
SEMA5A 0.014 0 0.30 2 
SH3TC1 0.014 0 0.04 4 
SPTB 0.014 1 0.26 11 
LECT2 0.015 0 0.35 3 
ESYT3 0.015 1 0.51 4 
     
ER+ breast cancer, “NS_all” SNPs 
RTN4RL1 1.8 x 10-5 1 4.37 10 
OR2W5 7.3 x 10-5 1 16.16 11 
CYSRT1 1.0 x 10-4 1 0.23 2 
RNF130 1.3 x 10-4 0 0.69 3 
GABPA 1.3 x 10-4 1 0.02 2 
TCHP 1.7 x 10-4 1 4.41 12 
NLRP6 1.9 x 10-4 0 5.57 13 
ZNF329 3.9 x 10-4 0 0.15 3 
LRRC59 4.2 x 10-4 1 0.42 4 
DGCR2 4.6 x 10-4 0 0.44 7 
CYLD 4.6 x 10-4 0 0.02 2 
ZNF441 4.8 x 10-4 1 7.73 7 
MUS81 5.4 x 10-4 0 6.86 5 
CAST 6.4 x 10-4 0 13.05 20 
TRIM58 6.5 x 10-4 1 3.13 6 
OR5H15 6.6 x 10-4 1 0.06 3 
ANGPTL4 6.6 x 10-4 1 0.84 5 
OR4F6 6.6 x 10-4 0 2.28 11 
MMEL1 7.4 x 10-4 1 4.17 22 
OPRD1 7.9 x 10-4 1 0.41 3 
	
	
	
	
43 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
OR5AP2 8.2 x 10-4 0 2.91 6 
RARA 9.1 x 10-4 1 2.53 2 
RAB5C 9.1 x 10-4 0 0.75 3 
KCNH2 9.3 x 10-4 0 5.15 7 
ORAI3 1.0 x 10-3 1 0.05 3 
ZNF652 1.0 x 10-3 1 0.99 4 
KIAA1407 1.0 x 10-3 1 5.70 21 
PTPN7 1.1 x 10-3 1 1.91 9 
WHSC1 1.2 x 10-3 1 2.73 9 
KIF3C 1.3 x 10-3 1 2.54 6 
USP26 1.3 x 10-3 1 0.15 4 
LPPR3 1.5 x 10-3 1 1.28 5 
MTDH 1.5 x 10-3 1 0.12 2 
PLSCR5 1.6 x 10-3 1 5.01 3 
CERS6 1.6 x 10-3 1 1.17 5 
PNMA1 1.6 x 10-3 0 4.20 3 
MTIF2 1.7 x 10-3 1 0.52 9 
HIVEP3 1.8 x 10-3 1 20.80 39 
SACS 1.9 x 10-3 0 18.44 51 
LYZ 1.9 x 10-3 1 2.39 4 
MEGF6 2.0 x 10-3 1 16.18 29 
TMPO 2.1 x 10-3 1 8.23 13 
NUP43 2.1 x 10-3 1 0.29 4 
OARD1 2.2 x 10-3 1 0.06 3 
NUP210L 2.3 x 10-3 0 3.80 18 
DIRC1 2.4 x 10-3 1 0.57 2 
CHRDL2 2.4 x 10-3 0 1.07 6 
GOLGA1 2.4 x 10-3 1 1.83 12 
RCBTB1 2.5 x 10-3 0 0.18 4 
CHRNB3 2.6 x 10-3 1 4.62 8 
     
ER+ breast cancer, “NS_broad” SNPs 
RTN4RL1 3.2 x 10-5 1 2.00 6 
RNF130 1.3 x 10-4 0 0.69 3 
GABPA 1.3 x 10-4 1 0.02 2 
OR5H15 3.5 x 10-4 1 0.05 2 
TCHP 3.9 x 10-4 1 4.35 11 
ZNF329 3.9 x 10-4 0 0.15 3 
LRRC59 4.2 x 10-4 1 0.42 4 
TBPL2 4.3 x 10-4 1 0.10 3 
DGCR2 4.6 x 10-4 0 0.44 7 
CYLD 4.6 x 10-4 0 0.02 2 
MUS81 5.4 x 10-4 0 6.86 5 
COQ2 5.4 x 10-4 0 0.08 2 
OR4F6 5.9 x 10-4 0 2.00 8 
	
	
	
	
44 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
ATP2B4 6.4 x 10-4 1 0.66 12 
IDS 6.6 x 10-4 0 1.92 5 
ANGPTL4 7.1 x 10-4 1 0.82 3 
GPRASP1 7.8 x 10-4 0 5.18 5 
OR5AP2 7.8 x 10-4 0 2.88 5 
RARA 9.1 x 10-4 1 2.53 2 
RAB5C 9.1 x 10-4 0 0.75 3 
LYZ 9.2 x 10-4 0 1.38 2 
ORAI3 1.0 x 10-3 1 0.05 3 
WHSC1 1.2 x 10-3 1 2.73 8 
CHRDL2 1.4 x 10-3 0 0.72 4 
MDGA2 1.4 x 10-3 0 0.23 6 
RNF151 1.5 x 10-3 0 0.08 2 
PLSCR5 1.6 x 10-3 1 5.01 3 
CERS6 1.6 x 10-3 1 1.17 5 
PNMA1 1.6 x 10-3 0 4.20 3 
FSHB 1.6 x 10-3 1 0.31 3 
PDCD6IP 1.7 x 10-3 0 0.15 3 
RAPGEF5 1.8 x 10-3 0 0.39 5 
IL17RB 1.8 x 10-3 1 5.75 5 
RNF125 1.9 x 10-3 0 3.35 3 
MYO16 2.0 x 10-3 1 0.95 10 
ALG12 2.1 x 10-3 1 5.59 7 
THBS3 2.1 x 10-3 1 0.88 6 
IGSF5 2.3 x 10-3 0 2.27 7 
ZUFSP 2.3 x 10-3 1 0.42 2 
MED13L 2.4 x 10-3 1 1.09 12 
DIRC1 2.4 x 10-3 1 0.57 2 
RCBTB1 2.5 x 10-3 0 0.18 4 
TGFBR3 2.5 x 10-3 1 1.37 8 
KIAA1407 2.6 x 10-3 1 5.47 18 
ZBTB45 2.7 x 10-3 0 0.08 3 
OR4C12 2.7 x 10-3 0 0.95 3 
SLC39A7 2.8 x 10-3 1 0.52 4 
AMIGO1 2.9 x 10-3 1 1.75 4 
GBP5 2.9 x 10-3 0 2.54 7 
ZNF534 3.0 x 10-3 0 3.30 2 
     
ER+ breast cancer, “NS_strict” SNPs 
FSCN3 2.3 x 10-4 1 0.06 3 
GUF1 7.0 x 10-4 0 0.22 3 
ZIM3 7.8 x 10-4 1 0.87 2 
TSC2 8.0 x 10-4 0 0.61 5 
TBPL2 9.1 x 10-4 0 0.09 2 
CDH19 1.2 x 10-3 0 0.43 2 
	
	
	
	
45 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
C1QTNF1 1.3 x 10-3 1 0.04 3 
DOCK8 1.4 x 10-3 0 1.28 6 
KIF14 1.5 x 10-3 1 0.34 3 
ECT2L 1.5 x 10-3 0 1.41 2 
ERCC2 1.5 x 10-3 1 0.14 6 
PDE4A 2.6 x 10-3 1 0.50 2 
SNX18 2.8 x 10-3 0 0.03 2 
GCOM1 2.9 x 10-3 0 1.90 3 
ACSF3 3.3 x 10-3 1 0.16 3 
FAM198B 3.5 x 10-3 1 0.56 5 
TTLL6 4.1 x 10-3 1 0.19 3 
IQGAP3 4.4 x 10-3 0 0.48 6 
PLA2R1 4.5 x 10-3 1 2.04 4 
IMPDH1 4.9 x 10-3 1 0.02 2 
GC 5.0 x 10-3 1 0.14 2 
RGMB 5.8 x 10-3 1 0.10 2 
NOX5 6.0 x 10-3 0 1.06 5 
RHBG 6.3 x 10-3 1 0.40 3 
PDHA2 6.3 x 10-3 0 4.88 6 
PCDHB1 6.5 x 10-3 0 0.32 2 
FTO 6.6 x 10-3 0 0.16 2 
SAG 7.1 x 10-3 0 3.43 3 
IQCA1 7.1 x 10-3 1 2.92 3 
HIVEP3 7.4 x 10-3 0 0.84 2 
SLC8A3 7.4 x 10-3 0 0.25 5 
SCIN 7.4 x 10-3 1 2.49 5 
ZSCAN29 7.6 x 10-3 0 0.05 2 
MRPS30 7.7 x 10-3 1 0.45 3 
ZNF544 7.8 x 10-3 0 0.32 2 
STK17A 8.2 x 10-3 0 0.18 2 
MACF1 8.6 x 10-3 0 3.03 9 
B4GALNT3 8.6 x 10-3 1 0.54 5 
PMS1 8.7 x 10-3 0 4.57 4 
KIF13B 8.7 x 10-3 1 0.59 4 
POMT1 8.9 x 10-3 0 1.33 4 
FAM105A 9.5 x 10-3 1 0.41 2 
CHD8 9.5 x 10-3 1 0.02 2 
GRK1 9.5 x 10-3 1 0.67 2 
SLC26A8 9.6 x 10-3 1 0.04 2 
PARK2 9.8 x 10-3 1 1.15 5 
TKTL2 0.010 0 4.20 6 
DNAH14 0.010 1 5.03 4 
RNFT2 0.010 1 0.06 2 
EBLN2 0.011 1 0.96 2 
     
     
	
	
	
	
46 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
ER- breast cancer, “NS_all” SNPs 
PDE4D 1.2 x 10-6 1 0.02 2 
PLEKHG5 2.2 x 10-5 1 9.36 18 
CCNDBP1 4.4 x 10-5 0 0.06 3 
DIMT1 5.8 x 10-5 0 0.03 2 
TEX12 1.6 x 10-4 0 0.20 2 
FMNL3 1.7 x 10-4 0 2.28 7 
MRPS31 2.1 x 10-4 1 1.16 3 
OCIAD2 2.4 x 10-4 0 2.99 5 
INSC 3.1 x 10-4 0 12.44 21 
DCX 3.4 x 10-4 0 0.05 2 
C12orf5 3.5 x 10-4 1 1.50 2 
OARD1 3.7 x 10-4 1 0.04 4 
DCDC5 3.8 x 10-4 1 13.91 17 
SNX19 4.0 x 10-4 0 1.92 10 
EXTL3 4.0 x 10-4 1 5.23 6 
TIGD7 4.5 x 10-4 1 2.44 11 
TLN2 5.6 x 10-4 0 6.08 37 
WEE1 5.8 x 10-4 1 3.09 2 
WDR96 6.1 x 10-4 0 13.61 36 
SEPP1 6.4 x 10-4 1 0.28 6 
ANKK1 7.7 x 10-4 0 14.48 21 
SPATA21 8.0 x 10-4 0 10.68 14 
OBSCN 8.3 x 10-4 0 75.61 136 
ACSL4 8.5 x 10-4 0 0.02 2 
FES 8.8 x 10-4 0 6.60 11 
PDIA6 9.6 x 10-4 0 0.72 5 
IFI16 9.8 x 10-4 0 5.77 13 
UGT1A9 1.0 x 10-3 1 0.11 3 
PCDHA11 1.2 x 10-3 1 3.60 11 
PDPR 1.2 x 10-3 0 10.82 11 
MXD3 1.2 x 10-3 1 1.18 4 
DNM3 1.2 x 10-3 0 0.02 2 
PRR5 1.3 x 10-3 0 5.38 7 
HOMER2 1.3 x 10-3 1 0.76 3 
NFIB 1.3 x 10-3 1 0.10 2 
NRL 1.5 x 10-3 1 0.99 3 
ARMC8 1.5 x 10-3 0 0.04 2 
YOD1 1.6 x 10-3 0 0.05 3 
CRYAB 1.6 x 10-3 0 0.07 3 
TPM3 1.7 x 10-3 0 2.14 2 
VTA1 1.8 x 10-3 1 1.57 6 
OR51V1 1.8 x 10-3 1 5.70 9 
TDRP 1.8 x 10-3 1 0.80 4 
AP1S3 1.9 x 10-3 0 1.93 6 
	
	
	
	
47 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
OXCT1 1.9 x 10-3 1 1.18 4 
KIAA2018 2.0 x 10-3 0 13.15 22 
TM4SF18 2.0 x 10-3 1 0.22 3 
ANXA7 2.1 x 10-3 0 1.21 9 
MRPL10 2.1 x 10-3 0 0.10 2 
B4GALT6 2.1 x 10-3 0 6.30 3 
     
ER- breast cancer, “NS_broad” SNPs 
PDE4D 1.2 x 10-6 1 0.02 2 
LRRC8D 1.8 x 10-5 0 0.26 3 
CCNDBP1 4.4 x 10-5 0 0.06 3 
MRPS31 9.8 x 10-5 1 1.12 2 
NCR1 1.1 x 10-4 0 0.50 2 
PLEKHG5 1.2 x 10-4 1 9.30 14 
FMNL3 1.7 x 10-4 0 2.28 7 
PDIA6 1.8 x 10-4 1 0.44 4 
ORC6 2.0 x 10-4 1 0.02 2 
SNX19 2.1 x 10-4 0 1.14 7 
OBSCN 2.6 x 10-4 0 54.48 100 
DCX 3.4 x 10-4 0 0.05 2 
EXTL3 4.0 x 10-4 1 5.23 6 
ADAMTS18 4.2 x 10-4 1 4.38 25 
WEE1 5.8 x 10-4 1 3.09 2 
WDR96 7.0 x 10-4 0 3.43 21 
ACSL4 8.5 x 10-4 0 0.02 2 
PROCA1 1.0 x 10-3 0 0.71 2 
PDPR 1.0 x 10-3 0 7.70 10 
C12orf66 1.0 x 10-3 0 0.03 3 
OR8K5 1.1 x 10-3 1 3.33 5 
DNM3 1.2 x 10-3 0 0.02 2 
MXD3 1.3 x 10-3 1 0.81 2 
NFIB 1.3 x 10-3 1 0.10 2 
INSC 1.5 x 10-3 0 12.00 19 
CRYAB 1.5 x 10-3 0 0.06 2 
ARMC8 1.5 x 10-3 0 0.04 2 
YOD1 1.6 x 10-3 0 0.05 3 
LRPAP1 1.7 x 10-3 0 4.10 7 
HAUS6 1.7 x 10-3 1 3.54 8 
TPM3 1.7 x 10-3 0 2.14 2 
CCDC28A 1.8 x 10-3 1 0.90 3 
VTA1 1.8 x 10-3 1 1.57 6 
PLEKHD1 1.8 x 10-3 1 0.02 2 
AP1S3 1.9 x 10-3 0 1.93 6 
PRR5 1.9 x 10-3 1 4.63 5 
ANXA7 2.1 x 10-3 0 1.21 9 
	
	
	
	
48 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
FDPS 2.1 x 10-3 0 2.47 5 
SIDT2 2.1 x 10-3 1 4.94 12 
BTBD3 2.2 x 10-3 0 0.23 3 
ZNF175 2.6 x 10-3 0 0.83 9 
TMEM135 2.8 x 10-3 0 3.54 6 
DCN 2.8 x 10-3 1 0.08 2 
SERPINE1 2.8 x 10-3 0 0.23 2 
CSF2RB 3.0 x 10-3 0 1.24 5 
DDX47 3.1 x 10-3 0 0.43 6 
TLN2 3.1 x 10-3 0 5.23 35 
COL18A1 3.1 x 10-3 0 22.31 21 
PROX2 3.2 x 10-3 0 2.73 2 
PDGFRA 3.3 x 10-3 0 0.97 6 
     
ER- breast cancer, “NS_strict” SNPs 
FBXL22 8.2 x 10-6 1 0.02 2 
CCNDBP1 3.8 x 10-5 0 0.05 2 
SCARB1 9.6 x 10-5 1 0.02 2 
QRSL1 9.8 x 10-5 0 0.07 2 
MFGE8 1.1 x 10-4 0 0.05 3 
PAH 4.4 x 10-4 1 0.05 3 
KIAA1522 5.3 x 10-4 0 0.08 3 
CTSE 5.7 x 10-4 0 0.15 2 
SPTBN5 6.2 x 10-4 1 0.06 3 
NRG2 1.3 x 10-3 1 0.07 3 
MCM4 1.4 x 10-3 1 0.07 3 
MYO5B 1.5 x 10-3 1 1.07 4 
RNF175 1.5 x 10-3 0 0.16 3 
HBS1L 1.6 x 10-3 1 0.21 2 
TMEM59 1.8 x 10-3 0 0.02 2 
FRAS1 2.0 x 10-3 1 0.38 8 
PLCG2 2.1 x 10-3 1 0.29 2 
WDR7 2.1 x 10-3 0 0.06 2 
GCKR 2.2 x 10-3 1 0.15 4 
AGER 2.2 x 10-3 1 0.21 2 
SPTB 2.6 x 10-3 1 0.24 11 
LOXHD1 2.9 x 10-3 0 0.17 4 
SLC4A3 3.1 x 10-3 0 0.02 2 
NFASC 3.1 x 10-3 0 0.04 2 
JAK3 3.1 x 10-3 1 0.03 2 
STK17A 3.6 x 10-3 0 0.17 2 
ANKRD6 3.8 x 10-3 0 0.02 2 
ZNF221 3.9 x 10-3 0 0.02 2 
PARD3 5.2 x 10-3 1 0.20 2 
RFTN2 5.3 x 10-3 0 0.02 2 
	
	
	
	
49 
Gene Nominal  p-value rho
a Cumulative  MAF (%) 
Number of SNPs  
included in the test 
REXO4 5.4 x 10-3 1 0.53 2 
COL6A6 5.7 x 10-3 0 0.73 5 
FAM159A 5.8 x 10-3 0 0.02 2 
COLEC10 5.9 x 10-3 1 0.02 2 
PDHA2 6.3 x 10-3 0 4.82 5 
ADHFE1 7.1 x 10-3 0 0.29 3 
IQCA1 7.6 x 10-3 0 2.82 3 
CCDC141 8.0 x 10-3 0 0.15 2 
NCAPD3 8.5 x 10-3 0 0.24 3 
TEX14 9.1 x 10-3 0 0.54 6 
SORBS3 0.010 1 0.32 3 
TEKT5 0.010 1 0.75 6 
GABRP 0.010 1 2.98 2 
LRRFIP2 0.010 0 0.36 4 
ADSSL1 0.011 0 0.03 2 
PRDM10 0.011 0 3.26 4 
USP45 0.011 0 1.00 6 
DNAH2 0.011 0 0.61 7 
GLOD5 0.011 0 0.39 2 
USH2A 0.012 0 1.37 7 
a The rho parameter indicates whether the SKAT test (rho = 0) or burden test (rho = 1) gave the 
smallest p-value. 
  
	
	
	
	
50 
Supplementary Table 1.S3:  The 50 most significant SNPs for overall, ER+, and ER- 
breast cancer. 
SNP rsID Minor allele MAF(%)
a OR (95% CI)b P-value 
Overall breast cancer 
exm1441731 rs8100241 A 39.7 0.84 (0.79, 0.90) 1.2 x 10-6 
exm408302 rs17003166 T 0.7 0.36 (0.22, 0.58) 2.1 x 10-5 
exm1427571 rs200584784 T 1.1 0.46 (0.32, 0.66) 2.4 x 10-5 
exm419455 rs73841072 C 1.4 1.79 (1.34, 2.37) 6.4 x 10-5 
exm-rs4784227 rs4784227 T 7.8 1.28 (1.13, 1.45) 8.9 x 10-5 
exm1650281 rs112891247 C 4.8 1.36 (1.16, 1.58) 1.1 x 10-4 
exm1533510 rs11907355 A 9.1 1.26 (1.12, 1.42) 1.2 x 10-4 
exm278555 rs149890791 A 1.7 1.68 (1.29, 2.20) 1.2 x 10-4 
exm216147 rs3087399 C 25.8 0.86 (0.80, 0.93) 1.4 x 10-4 
exm1113714 rs35129712 C 2.3 1.53 (1.23, 1.91) 1.5 x 10-4 
exm1545016 rs61750835 G 3.9 0.72 (0.60, 0.85) 2.2 x 10-4 
exm856699 rs2286735 A 22.3 0.86 (0.79, 0.93) 2.3 x 10-4 
exm1005644 rs10783518 C 10.9 1.24 (1.11, 1.39) 2.3 x 10-4 
exm441845 rs7705355 C 11.4 1.22 (1.10, 1.36) 2.4 x 10-4 
exm1003138 rs7954976 T 37.5 0.88 (0.82, 0.94) 2.4 x 10-4 
exm956254 rs111789052 G 6.5 0.77 (0.67, 0.89) 2.5 x 10-4 
exm1321588 rs115680799 T 4.6 1.34 (1.15, 1.57) 2.5 x 10-4 
exm-rs28421666 rs28421666 G 10.5 0.81 (0.73, 0.91) 2.5 x 10-4 
exm536684 rs241448 G 22.0 1.16 (1.07, 1.26) 2.7 x 10-4 
exm109222 rs149623112 T 0.9 0.49 (0.33, 0.72) 2.8 x 10-4 
exm-rs10751 rs10751 A 10.1 1.23 (1.10, 1.37) 3.0 x 10-4 
exm818712 rs1762526 A 25.5 0.87 (0.80, 0.94) 3.1 x 10-4 
exm2251529 rs9541763 A 40.9 1.13 (1.06, 1.21) 3.2 x 10-4 
exm1194756 rs140966649 G 0.7 2.13 (1.41, 3.21) 3.3 x 10-4 
exm869809 rs143829732 T 0.6 2.22 (1.44, 3.44) 3.4 x 10-4 
exm2253593 rs115741058 A 10.6 1.22 (1.09, 1.36) 3.6 x 10-4 
exm2268090 rs4556865 G 18.0 1.17 (1.07, 1.28) 3.7 x 10-4 
exm621981 rs17290103 C 2.6 1.45 (1.18, 1.79) 3.8 x 10-4 
exm645071 rs144198145 T 0.8 2.04 (1.38, 3.01) 3.9 x 10-4 
exm-rs2857101 rs2857101 C 14.8 1.18 (1.08, 1.30) 4.2 x 10-4 
exm155869 rs3795789 T 5.3 1.30 (1.12, 1.51) 5.1 x 10-4 
exm904482 rs7106654 A 29.9 1.14 (1.06, 1.23) 5.2 x 10-4 
exm333608 rs11537816 A 5.0 1.31 (1.13, 1.53) 5.2 x 10-4 
exm816118 rs61730101 T 6.3 0.78 (0.68, 0.90) 5.4 x 10-4 
exm51138 rs112235212 T 2.3 1.49 (1.19, 1.86) 5.6 x 10-4 
exm-rs13385731 rs13385731 C 5.5 1.29 (1.12, 1.49) 5.8 x 10-4 
exm-rs17837562 rs17837562 C 48.7 0.89 (0.83, 0.95) 5.8 x 10-4 
exm155760 rs3795785 T 4.5 1.33 (1.13, 1.56) 6.2 x 10-4 
exm2263920 rs7601254 A 36.9 0.89 (0.83, 0.95) 6.4 x 10-4 
exm1027449 rs3812813 T 19.1 0.86 (0.79, 0.94) 6.4 x 10-4 
exm2251956 rs1955619 T 47.3 1.12 (1.05, 1.20) 6.7 x 10-4 
exm511916 rs78013120 G 1.8 1.54 (1.20, 1.99) 7.1 x 10-4 
exm251846 rs7586970 C 35.4 1.13 (1.05, 1.21) 7.4 x 10-4 
exm2273203 rs5930935 C 39.6 1.12 (1.05, 1.20) 7.9 x 10-4 
exm225759 rs11686946 G 12.4 1.19 (1.08, 1.32) 8.1 x 10-4 
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SNP rsID Minor allele MAF(%)
a OR (95% CI)b P-value 
exm1005630 rs2292506 T 20.6 0.87 (0.80, 0.94) 8.2 x 10-4 
exm1386765 rs16951438 C 5.2 0.77 (0.66, 0.90) 8.2 x 10-4 
exm1541759 rs2235592 T 32.4 1.13 (1.05, 1.22) 8.3 x 10-4 
exm1398517 rs10401454 G 23.8 1.14 (1.06, 1.24) 8.9 x 10-4 
exm856748 rs3127106 C 36.7 0.89 (0.83, 0.95) 9.2 x 10-4 
 
ER+ breast cancer 
exm-rs4784227 rs4784227 T 7.8 1.39 (1.20, 1.61) 1.1 x 10-5 
exm419455 rs73841072 C 1.4 2.00 (1.45, 2.77) 2.9 x 10-5 
exm722938 rs7835830 T 30.4 0.83 (0.76, 0.90) 3.1 x 10-5 
exm1194756 rs140966649 G 0.7 2.58 (1.62, 4.09) 6.2 x 10-5 
exm869809 rs143829732 T 0.6 2.73 (1.67, 4.46) 6.6 x 10-5 
exm776144 rs147129385 C 0.7 2.43 (1.54, 3.83) 1.2 x 10-4 
exm1027449 rs3812813 T 19.1 0.82 (0.74, 0.91) 1.3 x 10-4 
exm-rs2857101 rs2857101 C 14.8 1.24 (1.11, 1.39) 1.4 x 10-4 
exm2253593 rs115741058 A 10.6 1.28 (1.12, 1.45) 1.9 x 10-4 
exm1512182 rs10422475 T 5.9 0.71 (0.59, 0.85) 2.1 x 10-4 
exm103720 rs114511335 C 0.9 2.16 (1.44, 3.25) 2.1 x 10-4 
exm707566 rs61734383 G 5.7 1.37 (1.16, 1.62) 2.4 x 10-4 
exm970437 rs7126904 A 27.2 0.84 (0.77, 0.92) 2.4 x 10-4 
exm817834 rs200076780 T 0.6 2.34 (1.48, 3.70) 2.5 x 10-4 
exm375664 rs2641776 G 1.4 1.80 (1.31, 2.48) 2.9 x 10-4 
exm2262115 rs9267873 C 10.7 0.78 (0.68, 0.89) 2.9 x 10-4 
exm1113714 rs35129712 C 2.3 1.61 (1.24, 2.08) 3.1 x 10-4 
exm928335 rs34891773 T 1.1 1.96 (1.36, 2.84) 3.2 x 10-4 
exm2251529 rs9541763 A 40.9 1.16 (1.07, 1.26) 3.3 x 10-4 
exm882948 rs16931292 C 5.0 0.70 (0.57, 0.85) 3.4 x 10-4 
exm-rs4962153 rs4962153 A 32.0 1.17 (1.07, 1.28) 3.4 x 10-4 
exm1386765 rs16951438 C 5.2 0.70 (0.58, 0.85) 3.5 x 10-4 
exm818712 rs1762526 A 25.5 0.84 (0.76, 0.93) 3.7 x 10-4 
exm1650281 rs112891247 C 4.8 1.39 (1.16, 1.67) 3.7 x 10-4 
exm1398517 rs10401454 G 23.8 1.19 (1.08, 1.30) 3.8 x 10-4 
exm468305 rs113315765 A 0.8 2.13 (1.40, 3.24) 3.9 x 10-4 
exm148404 rs61732016 G 0.6 0.28 (0.14, 0.57) 3.9 x 10-4 
exm1083904 rs140020925 A 1.5 1.71 (1.27, 2.29) 4.0 x 10-4 
exm-rs2968864 rs2968864 C 4.6 1.39 (1.16, 1.67) 4.2 x 10-4 
exm-rs9267546 rs9267546 A 24.6 1.18 (1.08, 1.30) 4.7 x 10-4 
exm1661225 rs145807417 C 1.5 0.50 (0.33, 0.74) 4.9 x 10-4 
exm1576078 rs34694890 G 1.9 1.65 (1.25, 2.19) 5.0 x 10-4 
exm110840 rs1952294 T 6.8 0.74 (0.63, 0.88) 5.0 x 10-4 
exm1380926 rs61734847 G 6.8 0.74 (0.62, 0.88) 5.3 x 10-4 
exm671435 rs1805123 G 4.6 1.38 (1.15, 1.66) 5.9 x 10-4 
exm2257141 rs62638621 A 5.1 1.36 (1.14, 1.63) 6.2 x 10-4 
exm339774 rs148353264 G 0.5 2.44 (1.46, 4.08) 6.3 x 10-4 
exm1003138 rs7954976 T 37.5 0.86 (0.79, 0.94) 6.5 x 10-4 
exm448472 rs61748196 C 2.3 0.59 (0.44, 0.80) 6.5 x 10-4 
exm2229479 rs1105561 C 20.5 1.19 (1.08, 1.31) 6.6 x 10-4 
exm447923 rs142643164 A 0.6 0.30 (0.15, 0.60) 7.0 x 10-4 
exm-rs10751 rs10751 A 10.1 1.26 (1.10, 1.43) 7.1 x 10-4 
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SNP rsID Minor allele MAF(%)
a OR (95% CI)b P-value 
exm531952 rs9267547 A 24.4 1.18 (1.07, 1.30) 7.2 x 10-4 
exm235622 rs144807087 C 1.6 1.70 (1.25, 2.32) 7.3 x 10-4 
exm1533510 rs11907355 A 9.1 1.27 (1.11, 1.46) 7.8 x 10-4 
exm2269048 rs13005516 T 46.5 1.15 (1.06, 1.25) 7.9 x 10-4 
exm952045 rs10895391 T 20.6 1.19 (1.07, 1.31) 7.9 x 10-4 
exm-rs7731657 rs7731657 C 23.7 1.18 (1.07, 1.29) 8.0 x 10-4 
exm1056807 rs78239814 A 1.7 1.69 (1.24, 2.29) 8.0 x 10-4 
exm1274174 rs8081370 C 2.3 1.54 (1.20, 1.99) 8.1 x 10-4 
      
ER- breast cancer 
exm1441731 rs8100241 A 39.7 0.75 (0.68, 0.84) 1.7 x 10-7 
exm904482 rs7106654 A 29.9 1.28 (1.14, 1.43) 1.7 x 10-5 
exm155869 rs3795789 T 5.3 1.59 (1.28, 1.96) 2.0 x 10-5 
exm588109 rs79486252 G 2.7 0.43 (0.29, 0.65) 3.9 x 10-5 
exm398843 rs115492433 T 1.1 2.50 (1.61, 3.86) 4.0 x 10-5 
exm1321588 rs115680799 T 4.6 1.59 (1.27, 1.98) 4.4 x 10-5 
exm2268262 rs530913 A 46.8 0.81 (0.73, 0.89) 4.6 x 10-5 
exm155332 rs141921462 A 2.4 1.87 (1.38, 2.53) 5.4 x 10-5 
exm699925 rs8178033 C 8.0 1.42 (1.20, 1.70) 7.6 x 10-5 
exm2264911 rs12725553 A 41.5 1.23 (1.11, 1.36) 1.0 x 10-4 
exm1420861 rs78494460 A 0.6 2.81 (1.67, 4.72) 1.0 x 10-4 
exm155760 rs3795785 T 4.5 1.55 (1.23, 1.95) 2.0 x 10-4 
exm113929 rs74122227 G 1.5 2.00 (1.39, 2.89) 2.1 x 10-4 
exm1427571 rs200584784 T 1.1 0.28 (0.14, 0.55) 2.2 x 10-4 
exm1193520 rs7496668 A 43.5 1.22 (1.10, 1.35) 2.4 x 10-4 
exm1526367 rs6034464 A 16.9 1.28 (1.12, 1.46) 2.4 x 10-4 
exm2264529 rs9540337 A 33.0 0.81 (0.73, 0.91) 2.5 x 10-4 
exm1001287 rs116557867 T 1.2 0.27 (0.13, 0.55) 2.7 x 10-4 
exm269207 rs11695248 T 43.3 0.83 (0.74, 0.92) 3.2 x 10-4 
exm1455742 rs116643737 T 1.1 2.16 (1.42, 3.29) 3.3 x 10-4 
exm956300 rs190009110 T 2.0 0.44 (0.29, 0.69) 3.3 x 10-4 
exm9525 rs76625876 T 2.0 1.82 (1.31, 2.53) 3.3 x 10-4 
exm1083370 rs114064896 A 4.1 1.57 (1.23, 2.00) 3.4 x 10-4 
exm971060 rs150787445 A 0.5 2.87 (1.61, 5.10) 3.4 x 10-4 
exm2272254 rs2243431 C 37.4 0.82 (0.74, 0.92) 3.5 x 10-4 
exm2271762 rs4278572 C 46.9 1.21 (1.09, 1.34) 3.6 x 10-4 
exm1190249 rs28510611 A 0.5 2.88 (1.60, 5.16) 4.1 x 10-4 
exm1417494 rs36038711 A 5.5 0.63 (0.49, 0.82) 4.4 x 10-4 
exm-rs1038304 rs1038304 A 20.9 0.80 (0.70, 0.91) 4.6 x 10-4 
exm387666 rs16840892 T 0.8 2.40 (1.47, 3.93) 4.7 x 10-4 
exm-rs2405657 rs2405657 A 25.6 1.23 (1.10, 1.38) 4.7 x 10-4 
exm2269177 rs4972618 C 39.2 1.20 (1.08, 1.33) 4.8 x 10-4 
exm408302 rs17003166 T 0.7 0.16 (0.06, 0.45) 4.9 x 10-4 
exm-rs10487524 rs10487524 A 7.0 0.69 (0.55, 0.85) 5.5 x 10-4 
exm775901 rs61738263 T 5.1 1.46 (1.18, 1.81) 5.7 x 10-4 
exm166600 rs869111 G 32.3 0.82 (0.73, 0.92) 6.3 x 10-4 
exm1581079 rs2839158 T 13.8 0.76 (0.65, 0.89) 6.4 x 10-4 
exm975476 rs149094984 T 1.4 1.94 (1.33, 2.85) 6.6 x 10-4 
exm946470 rs35073361 C 1.3 1.99 (1.34, 2.96) 6.7 x 10-4 
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SNP rsID Minor allele MAF(%)
a OR (95% CI)b P-value 
exm2272475 rs2740354 T 47.3 0.84 (0.76, 0.93) 6.8 x 10-4 
exm338170 rs35536878 C 9.9 1.33 (1.13, 1.57) 6.9 x 10-4 
exm1065133 rs34392264 T 0.9 2.28 (1.42, 3.67) 7.1 x 10-4 
exm699639 rs8178228 C 3.3 1.56 (1.21, 2.03) 7.3 x 10-4 
exm146417 rs34362403 A 1.4 0.37 (0.21, 0.66) 7.3 x 10-4 
exm270835 rs34353588 C 0.9 2.22 (1.40, 3.52) 7.3 x 10-4 
exm579506 rs34856068 T 2.0 1.80 (1.28, 2.53) 7.6 x 10-4 
exm2255498 rs6547014 C 44.9 1.19 (1.08, 1.32) 7.8 x 10-4 
exm2265086 rs1144836 A 11.8 0.75 (0.63, 0.89) 7.8 x 10-4 
exm692983 rs116659770 C 4.2 1.51 (1.19, 1.92) 7.9 x 10-4 
exm166656 rs61730407 G 24.4 0.81 (0.72, 0.92) 7.9 x 10-4 
Abbreviations: OR, odds ratio; CI, confidence interval. 
a Minor allele frequency in the AMBER study. 
b Odds ratio per minor allele. 
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Supplementary Figure 1.S1:  QQ plots for single SNP and gene-based analyses.  
Red: Overall breast cancer;  Green: ER+ breast cancer;  Blue: ER- breast cancer. 
Genomic control λ values (Overall, ER+, ER-):  Single SNP: 1.00,1.02,1.01;  Gene-based (GB) 
NS_all: 1.09,1.11,1.08;  GB NS_broad: 1.10,1.15,1.08;  GB NS_strict: 1.14,1.15,1.17. 
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Supplementary Figure 1.S2:  Cluster plots for the four SNPs that contributed to the 
significant gene-based tests for ER- breast cancer.   
Plotted points are ER- cases and controls that were genotyped together (excludes MEC).  In the 
plot legends, “exm*******_var” indicates the subject with one rare allele at SNP exm*******.
 
 
	
	
	
	
57 
 
 
	
	
	
	
58 
PROJECT 2 
 
Hormone-Related Pathways and Risk of Breast Cancer Subtypes  
in African American Women: the AMBER Consortium 
 
(Breast Cancer Research and Treatment 2015; 154(1): 145-154,  
with permission of Springer) 
 
 
 
ABSTRACT 
We sought to investigate genetic variation in hormone pathways in relation to risk 
of overall and subtype-specific breast cancer in women of African ancestry (AA).  
Genotyping and imputation yielded data on 143,934 SNPs in 308 hormone-related genes 
for 3663 breast cancer cases (1098 ER-, 1983 ER+, 582 ER unknown) and 4687 controls 
from the African American Breast Cancer Epidemiology and Risk (AMBER) 
Consortium.  AMBER includes data from four large studies of AA women: the Carolina 
Breast Cancer Study, the Women’s Circle of Health Study, the Black Women’s Health 
Study, and the Multiethnic Cohort Study.  Pathway- and gene-based analyses were 
conducted, and single SNP tests were run for the top genes.  There were no strong 
associations at the pathway level.  The most significantly associated genes were GHRH, 
CALM2, CETP, and AKR1C1 for overall breast cancer (gene-based nominal p ≤0.01); 
NR0B1, IGF2R, CALM2, CYP1B1, and GRB2 for ER+ breast cancer (p ≤0.02); and PGR, 
MAPK3, MAP3K1, and LHCGR for ER- disease (p ≤0.02).  Single-SNP tests for SNPs 
with pairwise linkage disequilibrium r2 <0.8 in the top genes identified 12 common SNPs 
(in CALM2, CETP, NR0B1, IGF2R, CYP1B1, PGR, MAPK3, and MAP3K1) associated 
with overall or subtype-specific breast cancer after gene-level correction for multiple 
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testing.  Rs11571215 in PGR (progesterone receptor) was the SNP most strongly 
associated with ER- disease.  In conclusion, we identified eight genes in hormone 
pathways that contain common variants associated with breast cancer in AA women after 
gene-level correction for multiple testing. 
 
INTRODUCTION 
 Women of African ancestry (AA) have been under-represented in genetic studies 
of breast cancer to date.  At the same time, AA women experience higher mortality from 
breast cancer compared to women of European ancestry (1) and are more likely to be 
diagnosed with estrogen receptor negative (ER-) tumors, which carry a poor prognosis 
(2–6).  Given these racial disparities, it is critical that more studies be conducted in AA 
women, taking advantage of their greater genetic variability to identify risk variants. 
There is extensive evidence that steroid hormones affect breast cancer risk. In 
vitro studies have shown that estrogens and other hormones promote breast cell 
proliferation (7,8), and estrogen metabolites may initiate DNA damage and mutations (9–
13).  Also, increased rates of mammary tumor development have been reported in rodents 
given estrogens (7,14).  In humans, reproductive and hormonal factors such as age at 
menarche, parity, lactation, and use of exogenous estrogens and progestogens are 
associated with the risk of breast cancer (15–23).  Prospective studies in humans have 
shown that low blood concentrations of sex-hormone-binding globulin (SHBG) (24,25) 
and increased estrogen (24–27) and androgen (24–28) concentrations are associated with 
an increased risk of breast cancer.  Hormonal profiles vary by race (29), and 
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polymorphisms in steroid hormone pathway genes have been linked to hormone levels 
(30–34).  Differences in population allele frequencies at these loci may contribute to 
racial disparities in breast cancer. 
At least three breast cancer GWAS loci, ESR1 (35), MAP3K1 (36), and ITPR1 
(37), fall within biological pathways related to steroid hormone metabolism.  ESR1 and 
MAP3K1 associations have also been replicated in AA populations (38–42).  Candidate 
gene studies conducted by the National Cancer Institute Breast and Prostate Cancer 
Cohort Consortium (BPC3) (7) in more than 6000 breast cancer cases and 8000 controls 
found no significant associations with 37 steroid hormone metabolism genes (7,34,43–
48).  However, the BPC3 subjects were mostly of European ancestry, and the list of 
assayed genes was limited.  Therefore, the present study in an African American 
population was initiated to evaluate a more comprehensive set of steroid hormone 
metabolism genes for associations with overall, ER+, and ER- breast cancer.  Given the 
small effect sizes seen for common susceptibility variants, the present analyses utilized 
pathway- and gene-based testing approaches in an attempt to identify important 
biological pathways and genes with multiple risk variants that might otherwise be missed 
in a SNP-based approach. 
 
METHODS 
Study Population 
The present analyses were conducted using data from the African American 
Breast Cancer Epidemiology and Risk (AMBER) Consortium, a collaboration of four of 
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the largest studies of breast cancer in African American women.  The AMBER 
Consortium (49) and the four individual studies – the Carolina Breast Cancer Study 
(CBCS) (50), the Women’s Circle of Health Study (WCHS) (51,52), the Black Women’s 
Health Study (BWHS) (53), and the Multiethnic Cohort (MEC) (54) – have been 
described previously, and each was granted Institutional Review Board approval.  All 
study subjects provided informed consent. 
Briefly, the CBCS is a population-based case-control study of women aged 20 to 
74 years that began in North Carolina in 1993.  Cases were identified through the North 
Carolina Central Cancer Registry’s rapid case ascertainment system, and controls were 
enrolled through 2001 using Division of Motor Vehicles lists (age <65 years) and Health 
Care Financing Administration lists (age ≥65).  Questionnaire data and samples for DNA 
analysis were obtained by interviewers in home visits.   
The WCHS is an ongoing case-control study that began in 2002 with 
ascertainment of cases aged 20 to 75 years from New York City hospitals, later 
expanding to several counties in New Jersey with case identification using the New 
Jersey State Cancer Registry’s rapid case ascertainment system.  Controls have been 
recruited through random digit dialing as well as community-based efforts (52).  In-
person interviewers collect risk factor data and obtain samples for DNA analysis. 
The BWHS is a prospective cohort study that began in 1995 when 59,000 African 
American women 21-69 years of age from across the United States completed a postal 
health questionnaire.  Breast cancer cases are identified by self-report in biennial follow-
up questionnaires, and cases are confirmed by medical records or from state cancer 
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registry data and the National Death Index.  Approximately 27,000 BWHS participants 
provided saliva samples for DNA analysis.   
The MEC study is a prospective cohort study in Hawaii and California that began 
in 1993 with the enrollment of men and women aged 45–75 years.  Data are collected 
through questionnaires mailed at 5-year intervals, and breast cancer cases are confirmed 
by linkage with the California and Hawaii state cancer registries and the National Death 
Index.  Blood samples were obtained from study subjects for DNA analysis. 
 Eligible cases were women with incident invasive breast cancer or ductal 
carcinoma in situ, with available DNA for genotyping.  For BWHS and MEC, controls 
were selected from among participants who did not have breast cancer, and were 
frequency matched to cases on 5-year age group and geographical region.  Determination 
of ER status for cases was based on pathology data from hospital records or cancer 
registry records. 
 
SNP Selection for Genotyping 
We selected eight pathways related to steroid hormone synthesis from the 
Molecular Signatures Database (MSigDB) (55).  These pathways contained a total of 261 
genes.  We also added some specific genes (N=47) that were not in those eight pathways 
but had been associated with reproductive traits in candidate gene studies.  Tag SNPs 
were then selected for all 308 genes +/- 10 kb flanking regions in order to capture (at r2 
≥0.8) as many SNPs as possible with minor allele frequency ≥10%, based on the 
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haplotype structure of the Yoruban population (YRI) in 1000 Genomes (56) 
(http://www.1000genomes.org/). 
 
Genotyping and QC 
Genotypes were attempted for 6936 study subjects from the BWHS, CBCS, and 
WCHS, and were completed with call rate >98% for 6828 participants, which included 
3130 cases (963 ER-, 1674 ER+, 493 ER unknown) and 3698 controls.  The SNPs 
selected for the present study were included as part of >159,000 custom content SNPs 
added to an Illumina Exome Beadchip in line with the aims of the AMBER project.  
SNPs that were monomorphic, had Hardy-Weinberg Equilibrium p <1x10-4, call rate 
<0.98, or had >1 Mendelian error in trios from HapMap (57), or >2 discordant calls in 
duplicate samples, were excluded.  A total of 9576 SNPs in the 308 genes of interest for 
this study were successfully genotyped and passed quality control.  The University of 
Washington performed imputation using the IMPUTE2 software (58) and the 1000 
Genomes Phase I multi-ethnic reference panel (5/21/2011 1000 Genomes data, December 
2013 haplotype release). 
Genetic data from 533 cases (135 ER-, 309 ER+, 89 ER unknown) and 989 
controls in the MEC were available from a previous GWAS on the Illumina Human 1M-
Duo chip (59), with SNPs imputed to the same release of 1000 Genomes.  Imputed 
genotypes from MEC were combined with imputed data for the BWHS, CBCS, and 
WCHS into a final data set.  After excluding variants with mismatching alleles or allele 
frequencies that were different by more than 0.15 in MEC vs. the other three studies, and 
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variants with allele frequencies <0.5% or imputation score info <0.5 in either study, the 
final data set for analysis contained 143,934 genotyped and imputed SNPs in the 308 
genes of interest.  The final sample size for analysis was 8350 total subjects: 3663 cases 
(1098 ER-, 1983 ER+, 582 ER unknown) and 4687 controls. 
Genotype principal components were computed using the smartpca program in 
the EIGENSOFT package (60).  Relationship checking using PLINK version 1.07 (61) 
identified several related subjects across and within the individual studies.  Relatives 
(N=156) and those with more extreme principal components (N=35) were flagged so that 
sensitivity analyses could be performed.  The principal components of genotype were 
tested for association with case status after accounting for the study covariates: study, 
DNA source (blood, saliva[Oragene], saliva[mouthwash]), and the matching variables 
age and geographic region.  No principal components were strongly associated with case 
status after controlling for these covariates.  For case status and subtype association 
analyses, we included principal components that were associated in the multivariable 
model with p <0.1. 
 
Association Analysis 
 Pooled, gene-based pathway analyses were conducted using the adaptive rank 
truncated product (ARTP) statistic (62) as implemented in the R package PIGE (63).  In 
brief, the ARTP statistic is the minimum p-value observed across a set of candidate 
truncation points K, each of which is used to calculate a test statistic equal to the product 
of the K most significant SNP p-values in a given gene (for gene-level tests) or the K 
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most significant gene p-values in a given pathway (for pathway tests).  Thus, the ARTP 
method is an attractive choice because it optimizes the number of SNP p-values 
combined in each gene-level test and the number of gene p-values combined in each 
pathway test.  Prior to implementing this approach, a subset of SNPs was selected such 
that all SNP pairs had linkage disequilibrium (LD) r2 <0.8, using the filter.R2 option in 
the R package AdaJoint (64).  We call this the “pruned-in” set of SNPs.  This pruning 
process was done to avoid capturing only one or two association signals for some genes 
due to correlations between their top SNPs.  Based on the program parameters chosen, 
the ARTP gene-level tests combined the optimal number of most significant SNP p-
values from among the top 10 pruned-in SNPs for each gene.  The ARTP pathway tests 
combined the optimal percentage (in 5% increments) of the most significant gene p-
values in each pathway, without exceeding 50%. 
 The single SNP association tests, required as input to do the ARTP analyses, were 
performed using logistic regression analyses of the imputed dosage genotype data.  All 
statistical models were adjusted for study, age, geographic region, DNA source, and 
genotype principal components 5, 6, and 8. 
 
RESULTS 
Pathway analyses yielded one nominal association, for the Steroid Biosynthetic 
Process Pathway with ER+ breast cancer (p = 0.046).  Given the eight pathways tested, 
this result was not considered to be significant or borderline.  Because of the null results 
seen at this level of analysis (Supplementary Table 2.S1) and our objective of implicating 
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specific genes and SNPs, we turned our focus to the gene-level test results. 
Gene-level testing produced a number of nominally significant associations with 
overall, ER+, and ER- breast cancer (Table 2.1), although none survived a Bonferroni 
correction based on the 308 genes tested (Supplementary Table 2.S1).  The top four genes 
for overall, ER+, and ER- breast cancer were selected for follow-up.  For overall breast 
cancer, the most significant gene was GHRH, with p = 0.001; the other top genes were 
CALM2, CETP, and AKR1C1, which all had p ≤0.01.  For ER+ breast cancer, NR0B1 was 
the most significant gene, with p = 0.001, and the other top genes, all with p ≤0.02, were 
IGF2R, CYP1B1, and GRB2 (as well as CALM2, which was also a top gene for overall 
breast cancer).  For ER- disease, PGR was the top result with p = 0.003, and the other top 
genes were MAPK3, MAP3K1, and LHCGR, each with p ≤0.02. 
Individual SNP associations within the 12 prioritized genes were then examined, 
and 17 SNPs across 11 of the 12 genes (none in GRB2) survived a within gene correction 
for multiple testing based on the number of SNPs pruned in for each gene.  We refer to 
these SNPs as “gene-wide significant”.  Five of these SNPs (two in GHRH and one in 
each of AKR1C1, MAP3K1, and LHCGR) were imputed SNPs with allele frequencies 
<1%; thus, we did not consider those SNPs further (or genes GHRH, AKR1C1, and 
LHCGR, which contained no other SNPs of interest).  Of the 12 remaining gene-wide 
significant SNPs, three were associated with overall breast cancer, four with ER+ breast 
cancer, and five with ER- disease (Table 2.2). 
CALM2 was the most significant gene of interest for overall breast cancer.  The 
most significant SNP in CALM2 was rs13032512 (p = 1.3x10-4).  The A allele at this SNP 
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had a frequency of 5.5% in AMBER controls and was associated with an increased risk 
of breast cancer (OR 1.33, 95% CI 1.15, 1.54).  The most significant SNP in the top ER+ 
gene, NR0B1, was rs138860909 (p = 3.4x10-4).  The A allele at this SNP had a frequency 
of 16.6% in AMBER controls and was associated with a decreased risk of ER+ breast 
cancer (OR 0.80, 95% CI 0.71, 0.90).  The most significant SNP in the top ER- gene, 
PGR, was rs11571215 (p = 1.0x10-5).  The C allele at this SNP had a frequency of 9.2% 
in AMBER controls and was associated with a decreased risk of ER- breast cancer (OR 
0.64, 95% CI 0.52, 0.78).  In addition, a common nonsynonymous coding SNP in gene 
CYP1B1 (rs10012) was associated with an odds ratio of 0.85 (95% CI 0.79, 0.92; p = 
1.1x10-4) for ER+ breast cancer.   
Given that the BWHS, WCHS, and CBCS subjects were genotyped and imputed 
together, separately from the MEC subjects, we checked and confirmed that the allele 
frequencies for the 12 common gene-wide significant SNPs were similar in the two 
groups (MEC vs. non-MEC).  Also, effect estimates were in the same direction and most 
were of similar magnitude (Supplementary Table 2.S2). 
As expected, the most significant genes – CALM2 for overall breast cancer, 
NR0B1 for ER+ breast cancer, and PGR for ER- disease – each contained multiple SNPs 
with gene-wide significance.  The two SNPs in CALM2 had r2 = 0.53, while the two 
SNPs in NR0B1 were not correlated (r2 = 0.07).  For PGR, two SNPs were strongly 
correlated (r2 = 0.74), but neither was strongly correlated with the third (r2 <0.5). 
Allele frequencies in AMBER controls and 1000 Genomes African samples were 
similar.  However, the minor allele frequencies for 10 of the 12 SNPs of interest were 
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lower in 1000 Genomes Europeans vs. Africans (Table 2.2).  Furthermore, five of the 12 
SNPs of interest had 1000 Genomes European allele frequencies <1%, and two of these 
were monomorphic in 1000 Genomes Europeans. 
 In a sensitivity analysis, we reanalyzed these 12 SNPs with exclusion of 156 first-
degree or second-degree relatives (identified via the genotypes), as well as 35 PCA 
outliers who clustered with HapMap 3 Europeans, Mexicans, or Asians.  With these 
exclusions, all odds ratios changed by ≤3%.  Therefore, results of the original analysis on 
the full sample remained the focus for interpretation. 
 
DISCUSSION 
Our analyses found eight genes that may be involved in the etiology of breast 
cancer in African American women:  CETP for overall breast cancer; CALM2 for overall 
and ER+ breast cancer; NR0B1, IGF2R, and CYP1B1 for ER+ disease; and PGR, 
MAPK3, and MAP3K1 for ER- disease. 
The most significant of these were CALM2 (overall breast cancer), NR0B1 (ER+), 
and PGR (ER-).  The most significant SNP in CALM2, intronic SNP rs13032512, is less 
common in 1000 Genomes European ancestry samples (2.2%) than in African samples 
(5.9%).  The other gene-wide significant SNP in CALM2, intronic SNP rs114416221, is 
rare in 1000 Genomes Europeans (0.1%).  CALM2 maps to chromosome 2p21 and is one 
of three genes that encode the protein calmodulin (CaM).  CALM2 was included in the 
present study because of CaM’s involvement in gonadotropin-releasing hormone (GnRH) 
signaling: GnRH induces calcium influx, which activates CaM leading to a variety of 
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downstream effects that result in gonadotropin gene expression (65).  Thus, CALM2 may 
impact breast cancer susceptibility through its effects on hormone synthesis. 
The most significant SNP in the NR0B1 region, rs138860909, is located about 2 
kb upstream of the gene.  This SNP is rare in 1000 Genomes European ancestry samples 
(0.3%).  NR0B1 maps to chromosome Xp21.2 and encodes the orphan nuclear receptor 
DAX-1, for which high expression has been associated with excellent survival in node-
negative breast cancer (66).  DAX-1 is expressed in tissues involved in steroid hormone 
function and acts as an anti-steroidogenic factor by serving as a corepressor for the 
expression of enzymes such as aromatase (67).  The ability of DAX-1 to inhibit 
aromatase expression suggests a possible role for NR0B1 variants in the etiology of ER+ 
breast cancer, consistent with our results showing that associations with the top NR0B1 
SNPs were restricted to ER+ disease. 
The most significant SNP in the PGR gene, intronic SNP rs11571215, is 
monomorphic in 1000 Genomes European ancestry samples.  PGR is the progesterone 
receptor gene, located on chromosome 11q22.1.  Multiple studies have reported breast 
cancer associations with PGR SNP rs1042838 (68–71), but a later, larger meta-analysis 
showed no association (72).  Breast cancer associations have also been reported in a 
small AA sample for rs590688 and rs10895054 (73).  These three SNPs were not 
associated with breast cancer in the present study.  Several studies have reported evidence 
that PGR variants modify the effect of hormone replacement therapy on breast cancer 
risk (74–76), and a few studies have reported PGR associations with mammographic 
density (77,78).  Still, the role of PGR variants in breast cancer development remains 
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uncertain.  Nevertheless, the associated variants in this AA study are of interest given that 
they are absent from or rare in European ancestry populations, the source of subjects for 
most prior studies. 
Associations observed for CYP1B1 are also of interest.  This gene contains two 
common missense SNPs that were gene-wide significant for ER+ breast cancer: rs10012 
(Arg48Gly) and rs1056827 (Ala119Ser).  These two SNPs have previously been 
associated with other cancers (prostate (79–81), lung (82), endometrial (81,83)) in mostly 
European samples.  Modest associations have also been reported for rs1056827 with 
breast cancer in recent meta-analyses (80,81), although another meta-analysis reported no 
association (84).  These two SNPs were correlated at r2 = 0.87 in AMBER, and only 
rs10012 remained after pruning. 
CYP1B1 maps to chromosome 2p22.2 and encodes the cytochrome P-450 1B1 
enzyme, which is expressed in breast tumors (85–87).  CYP1B1 is capable of activating a 
variety of carcinogens and is responsible for the 4-hydroxylation of estradiol (85,88), 
leading to the formation of carcinogenic semiquinones and quinones (82).  Our study 
suggested a protective effect for the 48Gly allele.  It is unclear what mechanism would 
explain such an effect given that this allele has been shown to cause enhanced activity of 
the CYP1B1 enzyme (89), which one might assume would lead to increased risk.  
However, the all cases odds ratio of 0.92 (95% CI 0.86, 0.99) in the current study is 
consistent with the odds ratio of 0.93 (95% CI 0.81, 1.08) reported for carriers of one Gly 
allele in the meta-analysis by Economopoulos and Sergentanis (84).  Another meta-
analysis reported an odds ratio of 0.93 (95% CI 0.79, 1.10) for the 48Gly variant based on 
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a recessive model (81).  While these modest associations were not significant in either 
meta-analysis, these studies did not conduct analyses by ER subtype, whereby we 
discovered a stronger ER+ association.  Further evidence of subtype-specific effects 
comes from Wen and colleagues who reported that patients carrying the 48Gly allele 
were less likely to have ER+ disease (90).  Also of note, prior studies have included 
mostly Caucasian subjects, and the 48Gly allele, with a frequency of 29.0% in 1000 
Genomes Europeans, is the major allele in African populations (57.4%). 
 One of the implicated genes from our study, MAP3K1, is a breast cancer GWAS 
locus (36).  Following its discovery, replication and fine mapping studies in Europeans, 
Asians, and AAs confirmed and identified a number of associated SNPs in this region 
(37,39,41,42,91–96).  Two of these SNPs, rs16886397 and rs832539, were analyzed in 
the present study.  Results for rs832539 were null, while rs16886397, previously shown 
to affect MAP3K1 transcription (96), was nominally associated with ER+ breast cancer 
(OR = 1.22 for the G allele, p = 0.044).  Of note, although MAP3K1 was one of the top 
ER- genes in our analysis, it was also nominally associated with ER+ disease (p = 0.023).  
None of the gene-wide significant MAP3K1 SNPs from our analysis were in high LD 
with the top MAP3K1 SNPs from the literature, based on 1000 Genomes African ancestry 
samples. 
Most of the SNPs of interest from the current study are of lower frequency in 
European vs. African populations.  This may explain why aside from MAP3K1, 
statistically significant associations have not been found for these same genes/variants in 
the numerous European breast cancer GWAS.  Reported gene associations may represent 
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the causal effects of one or multiple variants.  Therefore, although these analyses identify 
specific SNPs for follow-up, future work should consider the entire gene. 
Despite having over 3500 cases and 4500 controls, the present study had limited 
power to detect individual SNP associations of small magnitude as well as stronger 
associations for rare SNPs, especially for subtype analyses.  Nevertheless, it is the largest 
study to date on the genetics of breast cancer in African Americans.  Results from 
sensitivity analyses minimized concerns about potential bias from PCA outliers or 
inflation of test statistics by relatives in the study.  Most of the SNPs of interest presented 
here were imputed.  Although this is a potential limitation, we focused on common SNPs 
with high imputation info scores (Table 2.2). 
In summary, gene-based and single SNP analyses suggested that CALM2, CETP, 
NR0B1, IGF2R, CYP1B1, PGR, MAPK3, and MAP3K1 may be involved in the etiology 
of breast cancer in African American women.  The most significantly associated genes 
containing common SNPs of interest were CALM2 for overall breast cancer, NR0B1 for 
ER+ breast cancer, and PGR for ER- disease.  Several of the top SNPs identified here are 
rare or absent in European populations, possibly explaining their lack of discovery to this 
point. 
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Table 2.1:  Associations of genes from steroid hormone pathways with overall, ER+, 
and ER- breast cancer risk in the AMBER Consortium. 
Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
GHRH 166 101 1.0x10-3 0.16 0.41 
CALM2 158 78 5.0x10-3 0.013 0.48 
CETP 312 176 9.0x10-3 0.31 0.30 
AKR1C1 484 143 0.010 0.15 0.061 
CGA 101 53 0.013 0.074 0.74 
CAMK2A 555 331 0.016 0.13 0.41 
HSD17B3 509 191 0.018 0.022 0.27 
CAMK2G 224 69 0.018 0.20 0.14 
SULT1E1 206 89 0.028 0.32 0.12 
PRKCD 298 158 0.034 0.096 0.30 
ITPR2 3130 1251 0.041 0.36 0.61 
GSTP1 170 75 0.049 0.41 0.14 
NR0B1 79 68 0.067 1.0x10-3 0.88 
IGF2R 883 401 0.052 7.0x10-3 0.59 
CYP1B1 139 75 0.51 0.013 0.20 
GRB2 607 129 0.33 0.019 0.14 
SLC10A2 329 153 0.15 0.025 0.73 
DIO3 53 30 0.59 0.027 0.75 
CYP2R1 63 43 0.076 0.028 0.42 
ADCY9 1414 644 0.38 0.031 0.85 
PGR 711 202 0.47 0.61 3.0x10-3 
MAPK3 24 19 0.75 0.95 0.010 
MAP3K1 544 141 0.13 0.023 0.015 
LHCGR 426 224 0.84 0.81 0.020 
SULT2B1 604 290 0.27 0.59 0.026 
LSS 284 115 0.75 0.85 0.026 
PLCB3 83 54 0.060 0.62 0.029 
HSD17B2 677 296 0.12 0.18 0.037 
DPEP2 128 49 0.78 0.69 0.038 
MAP2K7 78 45 0.53 0.77 0.039 
FABP6 513 216 0.72 0.15 0.040 
PRKACA 99 51 0.71 0.64 0.044 
HSD11B2 45 24 0.82 0.54 0.048 
ACOT8 103 56 0.10 0.79 0.049 
Abbreviations: ER+, estrogen receptor positive; ER-, estrogen receptor negative. 
Nominally significant results in bold font. 
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Table 2.2:  Relation of SNPs selected from gene-based analyses to risk of overall, ER+, and ER- breast cancer in AMBER. 
Gene 
 Gene- 
wide  
alpha 
SNP 
Reference 
/ effect 
allele 
 Effect allele  
frequency (%): 
AMBER ctls, 
AFR, EUR 
Imputation r2a: 
All AMBER, 
BWHS/WCHS/CBCS, 
MEC 
3663 cases 
4687 controls 
1983 ER+ cases 
4687 controls 
1098 ER- cases 
4687 controls 
OR p-value OR p-value OR p-value 
SNPs Gene-Wide Significant for All Breast Cancer 
            
CALM2 6.4x10-4 rs13032512 G/A 5.5, 5.9, 2.2 0.92, 0.98, 0.77 1.33 1.3x10
-4 1.30 4.1x10-3 1.35 8.2x10-3 
rs114416221 T/G 2.6, 4.5, 0.1 0.97, 0.97, 0.97 1.43 3.6x10-4 1.58 8.9x10-5 1.40 0.026 
            
CETP 2.8x10-4 rs28888131 G/A 19.9, 19.4, 18.5 0.97, 0.98, 0.95 0.84 8.9x10-5 0.87 8.0x10-3 0.82 3.5x10-3 
            SNPs Gene-Wide Significant for ER+ Breast Cancer 
            
NR0B1 7.4x10-4 rs138860909 G/A 16.6, 22.8, 0.3 0.87, 0.87, 0.91 0.88 0.012 0.80 3.4x10
-4 1.00 0.97 
rs5927492 G/A 40.2, 34.7, 82.1 typed, typed, typed 1.06 0.095 1.15 6.8x10-4 0.94 0.21 
            
IGF2R 1.2x10-4 rs76778371 G/A 7.2, 4.8, 7.7 0.94, 0.93, 0.97 0.77 2.1x10-4 0.68 2.0x10-5 0.92 0.41 
            
CYP1B1 6.7x10-4 rs10012 G/C 50.8, 57.4, 29.0 0.99, 0.99, 0.98 0.92 0.023 0.85 1.1x10-4 1.01 0.81 
            SNPs Gene-Wide Significant for ER- Breast Cancer 
            
PGR 2.5x10-4 
rs11571215 T/C 9.2, 12.0, 0.0 0.97, 0.98, 0.93 0.90 0.083 1.02 0.75 0.64 1.0x10-5 
rs11571247 T/C 11.7, 14.4, 0.0 0.99, 1.00, 0.94 0.94 0.29 1.08 0.24 0.69 4.8x10-5 
rs2124761 C/A 17.5, 21.9, 0.7 0.99, 1.00, 0.94 0.90 0.020 0.96 0.48 0.76 1.6x10-4 
            
MAPK3 2.6x10-3 rs78564187 G/A 18.0, 21.0, 9.4 1.03, typed, 0.99 1.07 0.13 1.03 0.58 1.26 3.7x10-4 
            
MAP3K1 3.5x10-4 rs10075381 A/C 8.0, 3.6, 35.6 1.00, typed, 0.97 0.94 0.35 1.05 0.55 0.66 1.5x10-4 
            Abbreviations: ctls, controls; AFR, 1000 Genomes Project Phase 3 African samples; EUR, 1000 Genomes Project Phase 3 European samples; OR, odds 
ratio (adjusted for study, age, region, DNA source, and genotype principal components); typed, genotyped. 
Odds ratios in bold font indicate the phenotype (overall, ER+, or ER- breast cancer) for which the gene was a top hit and the SNP was gene-wide 
significant. CALM2 was a top hit for both overall and ER+ breast cancer, and the CALM2 SNP rs114416221 was gene-wide significant for both outcomes 
a The imputation r2 quality metric computed by PLINK version 1.90 (97) (https://www.cog-genomics.org/plink2). 
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Supplementary Table 2.S1:  Associations of all pathways and genes analyzed with 
overall, ER+, and ER- breast cancer risk in the AMBER Consortium. 
Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
KEGG Steroid Hormone Biosynthesis Pathway; p = 0.43, 0.52, 0.52 (All cases, ER+, ER-) 
AKR1C1 484 143 9.99x10-3 0.153 0.0609 
HSD17B3 509 191 0.0180 0.0220 0.269 
SULT1E1 206 89 0.0280 0.323 0.116 
HSD17B2 677 296 0.119 0.177 0.0370 
CYP11B2 255 122 0.150 0.344 0.806 
UGT2B10 825 143 0.181 0.225 0.394 
AKR1C4 422 123 0.193 0.443 0.0759 
CYP1A1 117 58 0.241 0.171 0.328 
UGT2A1 572 178 0.252 0.357 0.686 
SULT2B1 604 290 0.273 0.593 0.0260 
CYP21A2 39 35 0.275 0.109 0.812 
AKR1C3 1419 509 0.277 0.459 0.168 
AKR1C2 311 140 0.327 0.991 0.119 
CYP3A7 147 37 0.362 0.722 0.579 
HSD17B8 16 12 0.381 0.275 0.837 
CYP7B1 726 174 0.383 0.136 0.153 
CYP7A1 169 80 0.394 0.532 0.140 
UGT2B28 251 65 0.404 0.707 0.108 
AKR1D1 676 279 0.421 0.486 0.685 
UGT2B7 295 64 0.435 0.582 0.188 
HSD17B6 126 51 0.455 0.835 0.318 
HSD3B1 222 69 0.467 0.610 0.932 
CYP11A1 141 58 0.474 0.0629 0.983 
UGT2B15 334 140 0.508 0.386 0.0829 
CYP1B1 139 75 0.509 0.0130 0.196 
STS 321 116 0.528 0.490 0.429 
CYP11B1 227 70 0.594 0.233 0.549 
CYP3A5 452 110 0.595 0.961 0.537 
HSD17B7 185 59 0.611 0.701 0.959 
SRD5A1 291 105 0.622 0.849 0.476 
HSD11B1 369 132 0.625 0.721 0.307 
UGT2B17 352 85 0.668 0.755 0.954 
HSD17B1 82 39 0.709 0.895 0.641 
CYP3A43 269 95 0.730 0.446 0.997 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
COMT 221 131 0.734 0.125 0.351 
UGT1A3 261 102 0.757 0.414 0.950 
UGT1A8 941 303 0.761 0.730 0.668 
UGT1A1 64 38 0.806 0.721 0.920 
HSD11B2 45 24 0.817 0.543 0.0480 
UGT2B11 142 50 0.850 0.891 0.512 
UGT1A4 317 119 0.878 0.520 0.962 
CYP3A4 187 78 0.888 0.999 0.935 
HSD17B12 872 243 0.890 0.761 0.632 
HSD3B2 386 140 0.919 0.349 0.775 
UGT1A5 361 120 0.925 0.481 0.957 
UGT1A6 491 168 0.937 0.556 0.497 
UGT1A7 544 177 0.945 0.577 0.515 
UGT1A10 799 260 0.946 0.732 0.625 
CYP17A1 107 53 0.949 0.893 0.991 
UGT1A9 619 200 0.956 0.641 0.549 
SRD5A3 231 93 0.962 0.666 0.834 
SRD5A2 291 127 0.963 0.875 0.344 
UGT2A3 334 70 0.986 0.841 0.654 
UGT2B4 598 152 0.990 0.996 0.745 
CYP19A1 787 313 0.991 0.784 0.790 
      
Reactome Steroid Hormones Pathway; p = 0.47, 0.27, 0.78 
HSD17B3 509 191 0.0180 0.0220 0.269 
CYP2R1 63 43 0.0759 0.0280 0.422 
STARD5 129 88 0.132 0.234 0.0889 
CYP11B2 255 122 0.150 0.344 0.806 
STARD6 203 56 0.164 0.344 0.188 
CYP21A2 39 35 0.275 0.109 0.812 
CYP24A1 323 178 0.358 0.133 0.743 
STARD4 90 63 0.398 0.685 0.679 
GC 450 178 0.399 0.699 0.697 
LRP2 1565 750 0.454 0.861 0.607 
CUBN 2436 1016 0.464 0.673 0.0579 
HSD3B1 222 69 0.467 0.610 0.932 
CYP11A1 141 58 0.474 0.0629 0.983 
STAR 73 47 0.525 0.726 0.516 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
CYP11B1 227 70 0.594 0.233 0.549 
LGMN 386 228 0.597 0.822 0.320 
HSD11B1 369 132 0.625 0.721 0.307 
CYP27B1 15 14 0.743 0.953 0.205 
HSD3B2 386 140 0.919 0.349 0.775 
CYP17A1 107 53 0.949 0.893 0.991 
CYP19A1 787 313 0.991 0.784 0.790 
      
Steroid Biosynthetic Process Pathway; p = 0.71, 0.046, 0.77 
NR0B1 79 68 0.0669 9.99x10-4 0.882 
SCP2 1101 201 0.0869 0.549 0.0879 
CYP11B2 255 122 0.150 0.344 0.806 
DHCR24 353 131 0.160 0.168 0.241 
NSDHL 204 119 0.181 0.161 0.472 
BMP6 1051 449 0.181 0.835 0.747 
SOD1 42 21 0.187 0.115 0.237 
CYP7B1 726 174 0.383 0.136 0.153 
CYP39A1 676 173 0.387 0.292 0.700 
AKR1D1 676 279 0.421 0.486 0.685 
HSD3B1 222 69 0.467 0.610 0.932 
CYP11A1 141 58 0.474 0.0629 0.983 
TFCP2L1 519 258 0.659 0.170 0.871 
HSD3B7 17 11 0.660 0.805 0.912 
NPC1L1 220 123 0.737 0.366 0.847 
ADM 85 41 0.785 0.555 0.669 
HSD11B2 45 24 0.817 0.543 0.0480 
CNBP 127 64 0.873 0.854 0.433 
NR5A1 208 110 0.889 0.694 0.586 
FDXR 107 47 0.912 0.674 0.126 
FDPS 49 33 0.964 0.554 0.347 
CYP19A1 787 313 0.991 0.784 0.790 
DHCR7 173 60 0.998 0.925 0.989 
      
Steroid Binding Pathway; p = 0.24, 1.0, 0.54 
CETP 312 176 8.99x10-3 0.315 0.305 
SCP2 1101 201 0.0869 0.549 0.0879 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
PGRMC1 53 41 0.226 0.519 0.0979 
APOF 49 23 0.299 0.662 0.124 
SHBG 152 79 0.299 0.439 0.461 
OSBP 272 79 0.367 0.453 0.0889 
GC 450 178 0.399 0.699 0.697 
AKR1D1 676 279 0.421 0.486 0.685 
PGRMC2 141 49 0.568 0.960 0.448 
ESR2 619 208 0.640 0.437 0.874 
STARD3 137 45 0.653 0.789 0.198 
CAV1 1127 300 0.659 0.978 0.503 
HSD17B4 665 180 0.679 0.626 0.899 
NPC2 119 48 0.694 0.914 0.619 
ALDH1A1 1069 354 0.747 0.943 0.672 
TSPO 175 95 0.794 0.528 0.177 
SYP 35 18 0.815 0.239 0.770 
APOA1 52 34 0.962 0.639 0.439 
      
Reactome Endogenous Sterols Pathway; p = 0.92, 0.20, 0.87 
CYP11B2 255 122 0.150 0.344 0.806 
CYP21A2 39 35 0.275 0.109 0.812 
CYP7B1 726 174 0.383 0.136 0.153 
CYP39A1 676 173 0.387 0.292 0.700 
CYP7A1 169 80 0.394 0.532 0.140 
CYP27A1 245 92 0.433 0.329 0.614 
CYP11A1 141 58 0.474 0.0629 0.983 
CYP1B1 139 75 0.509 0.0130 0.196 
CYP8B1 99 58 0.564 0.780 0.457 
CYP46A1 358 185 0.585 0.484 0.729 
CYP11B1 227 70 0.594 0.233 0.549 
CYP17A1 107 53 0.949 0.893 0.991 
CYP51A1 95 32 0.986 0.869 0.908 
CYP19A1 787 313 0.991 0.784 0.790 
      
Reactome Hormone Biosynthesis Pathway; p = 0.52, 0.48, 0.92 
CGA 101 53 0.0130 0.0739 0.742 
HSD17B3 509 191 0.0180 0.0220 0.269 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
CYP2R1 63 43 0.0759 0.0280 0.422 
PCSK1 399 164 0.126 0.310 0.264 
STARD5 129 88 0.132 0.234 0.0889 
CYP11B2 255 122 0.150 0.344 0.806 
STARD6 203 56 0.164 0.344 0.188 
DBH 311 210 0.207 0.293 0.397 
LTC4S 7 6 0.241 0.0569 0.565 
CYP21A2 39 35 0.275 0.109 0.812 
POMC 68 47 0.288 0.359 0.807 
IYD 520 233 0.320 0.795 0.398 
AANAT 102 77 0.343 0.204 0.363 
CYP24A1 323 178 0.358 0.133 0.743 
PTGIS 499 247 0.373 0.155 0.750 
STARD4 90 63 0.398 0.685 0.679 
GC 450 178 0.399 0.699 0.697 
ABCC1 1534 712 0.412 0.270 0.306 
LRP2 1565 750 0.454 0.861 0.607 
CUBN 2436 1016 0.464 0.673 0.0579 
ALOX5 570 194 0.467 0.527 0.578 
HSD3B1 222 69 0.467 0.610 0.932 
CYP11A1 141 58 0.474 0.0629 0.983 
SLC5A5 285 121 0.523 0.746 0.414 
STAR 73 47 0.525 0.726 0.516 
TPO 1554 624 0.573 0.737 0.883 
DIO3 53 30 0.588 0.0270 0.745 
CYP11B1 227 70 0.594 0.233 0.549 
LGMN 386 228 0.597 0.822 0.320 
TH 74 60 0.617 0.816 0.429 
DDC 970 261 0.623 0.241 0.560 
HSD11B1 369 132 0.625 0.721 0.307 
PNMT 18 15 0.674 0.497 0.354 
DIO2 78 45 0.690 0.818 0.893 
CGB 154 105 0.693 0.555 0.595 
LTA4H 325 155 0.693 0.842 0.661 
TBXAS1 1399 688 0.698 0.756 0.343 
PTGES3 175 56 0.712 0.929 0.783 
DIO1 213 84 0.722 0.426 0.391 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
LHB 61 29 0.739 0.639 0.539 
CYP27B1 15 14 0.743 0.953 0.205 
DPEP2 128 49 0.775 0.692 0.0380 
FSHB 71 23 0.816 0.516 0.682 
PTGS1 340 170 0.818 0.907 0.934 
GGT5 272 126 0.890 0.999 0.399 
TSHB 179 68 0.891 0.821 0.819 
TPH1 153 66 0.904 0.709 0.972 
HSD3B2 386 140 0.919 0.349 0.775 
CYP17A1 107 53 0.949 0.893 0.991 
PTGS2 173 62 0.974 0.824 0.164 
CYP19A1 787 313 0.991 0.784 0.790 
      
Reactome Steroid Metabolism Pathway; p = 0.83, 0.79, 0.68 
HSD17B3 509 191 0.0180 0.0220 0.269 
SLC27A5 127 69 0.0539 0.372 0.0549 
EBP 36 21 0.0709 0.116 0.212 
SCP2 1101 201 0.0869 0.549 0.0879 
ACOT8 103 56 0.102 0.794 0.0490 
ABCB11 903 380 0.128 0.389 0.788 
STARD5 129 88 0.132 0.234 0.0889 
CYP11B2 255 122 0.150 0.344 0.806 
SLC10A2 329 153 0.151 0.0250 0.734 
DHCR24 353 131 0.160 0.168 0.241 
STARD6 203 56 0.164 0.344 0.188 
MVK 180 57 0.164 0.121 0.237 
NSDHL 204 119 0.181 0.161 0.472 
IDI2 65 35 0.185 0.369 0.882 
AKR1C4 422 123 0.193 0.443 0.0759 
CYP21A2 39 35 0.275 0.109 0.812 
MSMO1 231 106 0.298 0.698 0.541 
ALB 158 59 0.339 0.455 0.407 
HMGCS1 219 53 0.367 0.215 0.167 
CYP7B1 726 174 0.383 0.136 0.153 
CYP39A1 676 173 0.387 0.292 0.700 
CYP7A1 169 80 0.394 0.532 0.140 
STARD4 90 63 0.398 0.685 0.679 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
SQLE 224 75 0.406 0.151 0.155 
IDI1 78 28 0.419 0.618 0.276 
AKR1D1 676 279 0.421 0.486 0.685 
CYP27A1 245 92 0.433 0.329 0.614 
GGPS1 130 28 0.445 0.916 0.765 
PMVK 107 48 0.451 0.419 0.325 
HSD3B1 222 69 0.467 0.610 0.932 
CYP11A1 141 58 0.474 0.0629 0.983 
STAR 73 47 0.525 0.726 0.516 
CYP8B1 99 58 0.564 0.780 0.457 
CYP46A1 358 185 0.585 0.484 0.729 
SLCO1B3 2412 502 0.586 0.521 0.204 
CYP11B1 227 70 0.594 0.233 0.549 
HSD17B7 185 59 0.611 0.701 0.959 
HSD11B1 369 132 0.625 0.721 0.307 
SC5DL 157 61 0.633 0.363 0.233 
ABCC3 300 206 0.646 0.970 0.332 
HSD3B7 17 11 0.660 0.805 0.912 
SLC10A1 198 52 0.662 0.206 0.221 
HSD17B4 665 180 0.679 0.626 0.899 
FABP6 513 216 0.715 0.147 0.0400 
LBR 245 94 0.732 0.674 0.694 
LSS 284 115 0.750 0.849 0.0260 
CH25H 113 38 0.810 0.626 0.825 
MVD 121 84 0.834 0.359 0.759 
SLCO1B1 1025 326 0.872 0.817 0.816 
SLC27A2 473 164 0.877 0.760 0.834 
BAAT 238 72 0.884 0.744 0.532 
SLCO1A2 1068 339 0.889 0.794 0.377 
FDFT1 702 319 0.894 0.493 0.821 
ACOX2 197 116 0.903 0.679 0.893 
HSD3B2 386 140 0.919 0.349 0.775 
CYP17A1 107 53 0.949 0.893 0.991 
AMACR 185 105 0.966 0.802 0.786 
CYP51A1 95 32 0.986 0.869 0.908 
CYP19A1 787 313 0.991 0.784 0.790 
HMGCR 169 64 0.993 0.958 0.304 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
TM7SF2 24 17 0.993 0.913 0.759 
DHCR7 173 60 0.998 0.925 0.989 
      
KEGG GnRH Signaling Pathway; p = 0.30, 0.71, 0.49 
CALM2 158 78 5.00x10-3 0.0130 0.479 
CGA 101 53 0.0130 0.0739 0.742 
CAMK2A 555 331 0.0160 0.135 0.413 
CAMK2G 224 69 0.0180 0.200 0.138 
PRKCD 298 158 0.0340 0.0959 0.296 
ITPR2 3130 1251 0.0410 0.360 0.612 
MAPK8 763 122 0.0529 0.0569 0.166 
EGFR 1177 585 0.0539 0.0919 0.297 
SRC 463 285 0.0579 0.379 0.106 
PLCB3 83 54 0.0599 0.624 0.0290 
PLA2G2C 156 74 0.0659 0.321 0.109 
PLA2G5 502 176 0.0779 0.230 0.164 
MAP3K1 544 141 0.128 0.0230 0.0150 
MMP14 157 120 0.153 0.718 0.284 
CALM1 168 90 0.153 0.327 0.948 
MMP2 314 162 0.167 0.405 0.492 
GNRH1 16 12 0.171 0.413 0.306 
CAMK2B 650 318 0.197 0.329 0.423 
CALM3 153 93 0.201 0.375 0.353 
PTK2B 987 286 0.212 0.328 0.0529 
ADCY6 145 72 0.213 0.426 0.243 
PLA2G4B 70 20 0.226 0.139 0.283 
PLA2G4A 1118 410 0.235 0.403 0.145 
PLA2G10 22 10 0.241 0.609 0.0909 
MAP3K3 395 86 0.249 0.447 0.208 
PLD2 192 121 0.249 0.900 0.285 
ADCY7 358 194 0.263 0.891 0.556 
RAF1 558 111 0.267 0.338 0.308 
JUN 87 51 0.275 0.624 0.471 
CACNA1C 3894 1958 0.276 0.251 0.654 
MAPK12 91 54 0.285 0.239 0.358 
CACNA1D 1853 909 0.288 0.991 0.130 
PLA2G6 566 168 0.304 0.467 0.475 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
MAP3K4 913 240 0.315 0.911 0.580 
CALML6 74 46 0.315 0.664 0.729 
ATF4 76 36 0.316 0.541 0.0959 
CAMK2D 1979 722 0.316 0.172 0.372 
PRKX 774 550 0.327 0.576 0.0989 
GRB2 607 129 0.334 0.0190 0.143 
PLA2G1B 119 53 0.337 0.150 0.294 
CALML3 81 61 0.340 0.308 0.499 
PLA2G3 80 63 0.342 0.276 0.794 
ITPR1 2722 1636 0.359 0.554 0.333 
ADCY5 1183 466 0.365 0.594 0.471 
ADCY9 1414 644 0.379 0.0310 0.853 
SOS2 687 143 0.379 0.395 0.890 
NRAS 72 35 0.385 0.267 0.803 
CACNA1S 706 419 0.392 0.156 0.904 
PLCB1 5385 2164 0.399 0.0509 0.933 
MAPK14 467 101 0.405 0.620 0.424 
PRKCB 2669 1171 0.412 0.153 0.826 
PRKCA 3452 1216 0.429 0.781 0.176 
GNRHR 189 89 0.441 0.489 0.792 
MAP2K3 158 113 0.444 0.427 0.431 
PLA2G2A 191 107 0.454 0.702 0.487 
GNAQ 1463 355 0.467 0.140 0.526 
HBEGF 128 71 0.476 0.845 0.726 
MAP2K6 780 380 0.498 0.240 0.520 
MAP2K7 78 45 0.527 0.772 0.0390 
PLD1 1264 331 0.530 0.405 0.396 
CDC42 358 111 0.546 0.214 0.638 
ADCY8 2048 633 0.553 0.693 0.465 
PRKACB 819 160 0.557 0.951 0.130 
GNRH2 33 16 0.588 0.642 0.370 
PLCB4 2198 777 0.595 0.245 0.847 
MAP2K1 685 144 0.605 0.653 0.267 
GNAS 365 201 0.609 0.224 0.999 
PLA2G2F 154 93 0.659 0.850 0.860 
JMJD7-PLA2G4B 118 51 0.669 0.712 0.519 
PLA2G12B 109 50 0.669 0.798 0.608 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
PRKACG 69 46 0.673 0.509 0.842 
MAP3K2 297 78 0.674 0.725 0.597 
MAPK11 82 50 0.675 0.766 0.207 
MAPK1 692 149 0.693 0.238 0.628 
KRAS 334 122 0.704 0.414 0.538 
PRKACA 99 51 0.712 0.644 0.0440 
ADCY1 786 318 0.718 0.493 0.720 
SOS1 691 171 0.723 0.395 0.835 
LHB 61 29 0.739 0.639 0.539 
MAPK9 559 250 0.745 0.844 0.688 
MAPK3 24 19 0.747 0.951 9.99x10-3 
CACNA1F 58 26 0.771 0.376 0.607 
HRAS 120 57 0.801 0.771 0.627 
PLCB2 195 119 0.803 0.634 0.725 
MAPK13 125 74 0.804 0.747 0.430 
PLA2G2E 147 87 0.807 0.676 0.103 
FSHB 71 23 0.816 0.516 0.682 
ITPR3 611 282 0.830 0.212 0.963 
MAP2K4 518 173 0.855 0.331 0.278 
CALML5 149 95 0.875 0.650 0.155 
PLA2G2D 207 126 0.893 0.507 0.806 
PLA2G4E 734 287 0.904 0.637 0.993 
ADCY3 732 272 0.911 0.905 0.290 
ELK1 51 25 0.916 0.840 0.808 
GNA11 306 158 0.962 0.938 0.643 
ADCY4 108 74 0.962 0.931 0.849 
MAP2K2 324 152 0.963 0.986 0.234 
MAPK10 1898 515 0.963 0.940 0.398 
ADCY2 2836 1079 0.969 0.968 0.180 
PLA2G12A 168 87 0.977 0.976 0.154 
MAPK7 7 7 0.983 0.881 0.983 
      
Selected based on published studies 
GHRH 166 101 9.99x10-4 0.158 0.411 
GSTP1 170 75 0.0490 0.412 0.143 
IGF2R 883 401 0.0519 6.99x10-3 0.592 
SSTR4 78 35 0.141 0.321 0.302 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
SSTR5 126 79 0.145 0.159 0.153 
IGFBP6 76 45 0.151 0.156 0.425 
PRLR 1292 453 0.155 0.864 0.390 
IGFBP4 154 85 0.156 0.306 0.831 
SST 118 53 0.229 0.401 0.331 
NQO1 136 48 0.251 0.223 0.622 
GHRHR 229 138 0.253 0.379 0.804 
SSTR3 236 129 0.254 0.686 0.0529 
ESR1 2506 921 0.262 0.569 0.174 
INSR 1595 818 0.262 0.495 0.510 
SULT1A1 124 66 0.263 0.515 0.807 
IGF1R 2171 1077 0.292 0.557 0.631 
GHR 1569 453 0.299 0.636 0.873 
FSHR 1595 580 0.323 0.464 0.912 
IGFALS 198 65 0.334 0.133 0.641 
CYP1A2 128 44 0.354 0.664 0.272 
SULT2A1 300 144 0.365 0.246 0.631 
INHBB 125 90 0.411 0.147 0.950 
NAT2 330 116 0.419 0.497 0.290 
CYP2C9 493 80 0.461 0.879 0.680 
PGR 711 202 0.472 0.612 3.00x10-3 
IRS2 311 169 0.482 0.540 0.380 
POU1F1 123 49 0.551 0.613 0.248 
PRL 192 104 0.578 0.494 0.659 
NAT1 686 322 0.599 0.647 0.225 
AR 302 84 0.608 0.862 0.214 
IGF2 186 115 0.634 0.397 0.537 
MC2R 502 171 0.663 0.294 0.394 
SSTR2 147 89 0.663 0.592 0.656 
IGFBP5 219 122 0.684 0.187 0.665 
IGF1 323 127 0.704 0.914 0.215 
SULT1A2 36 18 0.723 0.588 0.946 
INHA 76 42 0.744 0.341 0.855 
ACVR1 725 288 0.746 0.628 0.975 
IGFBP2 263 143 0.751 0.380 0.611 
INHBA 36 20 0.753 0.234 0.840 
SOD2 138 61 0.811 0.180 0.495 
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Gene Number of SNPs 
Number of 
SNPs retained 
after pruning 
All cases 
p-value 
ER+ 
p-value 
ER-  
p-value 
ACVR2A 291 71 0.830 0.760 0.706 
LHCGR 426 224 0.836 0.810 0.0200 
SSTR1 115 68 0.887 0.997 0.220 
IRS1 373 154 0.955 0.591 0.501 
IGFBP3 128 69 0.977 0.698 0.719 
IGFBP1 158 68 0.992 0.902 0.665 
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Supplementary Table 2.S2:  Relation of SNPs selected from gene-based analyses to risk of overall, ER+, and ER- breast 
cancer, by genotyping project (BWHS/WCHS/CBCS vs. MEC). 
Gene SNP 
Reference 
/ effect 
allele 
Sample 
 Effect allele 
frequency in 
controls (%) 
Imputation 
r2a 
All cases ER+ ER- 
OR p-value OR p-value OR p-value 
SNPs Gene-Wide Significant for All Breast Cancer 
CALM2 rs13032512 G/A All AMBERb 5.5 0.92 1.33 1.3x10-4 1.30 4.1x10-3 1.35 8.2x10-3 
   BWHS/WCHS/CBCSc 4.3 0.98 1.38 3.4x10-4 1.35 4.5x10-3 1.37 0.017 
   MECd 9.8 0.77 1.23 0.13 1.18 0.34 1.31 0.24 
   1000G AFR, EUR 5.9, 2.2        
            
 rs114416221 T/G All AMBER 2.6 0.97 1.43 3.6x10-4 1.58 8.9x10-5 1.40 0.026 
   BWHS/WCHS/CBCS 2.6 0.97 1.44 1.4x10-3 1.51 1.9x10-3 1.46 0.019 
   MEC 2.6 0.97 1.42 0.11 1.90 9.3x10-3 1.08 0.85 
   1000G AFR, EUR 4.5, 0.1        
            
CETP rs28888131 G/A All AMBER 19.9 0.97 0.84 8.9x10-5 0.87 8.0x10-3 0.82 3.5x10-3 
   BWHS/WCHS/CBCS 19.5 0.98 0.86 1.7x10-3 0.88 0.028 0.86 0.038 
   MEC 21.7 0.95 0.79 0.016 0.84 0.15 0.63 0.014 
   1000G AFR, EUR 19.4, 18.5        
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Gene SNP 
Reference 
/ effect 
allele 
Sample 
 Effect allele 
frequency in 
controls (%) 
Imputation 
r2a 
All cases ER+ ER- 
OR p-value OR p-value OR p-value 
SNPs Gene-Wide Significant for ER+ Breast Cancer 
NR0B1 rs138860909 G/A All AMBER 16.6 0.87 0.88 0.012 0.80 3.4x10-4 1.00 0.97 
   BWHS/WCHS/CBCS 16.6 0.87 0.85 3.6x10-3 0.79 5.3x10-4 0.91 0.25 
   MEC 16.3 0.91 1.01 0.93 0.85 0.23 1.53 0.010 
   1000G AFR, EUR 22.8, 0.3        
            
 rs5927492 G/A All AMBER 40.2 genotyped 1.06 0.095 1.15 6.8x10-4 0.94 0.21 
   BWHS/WCHS/CBCS 39.7 genotyped 1.03 0.40 1.13 9.7x10-3 0.93 0.21 
   MEC 42.1 genotyped 1.18 0.036 1.28 0.011 0.97 0.79 
   1000G AFR, EUR 34.7, 82.1        
            
IGF2R rs76778371 G/A All AMBER 7.2 0.94 0.77 2.1x10-4 0.68 2.0x10-5 0.92 0.41 
   BWHS/WCHS/CBCS 7.1 0.93 0.83 0.016 0.75 4.1x10-3 0.96 0.68 
   MEC 7.5 0.97 0.55 8.4x10-4 0.40 2.3x10-4 0.74 0.30 
   1000G AFR, EUR 4.8, 7.7        
            
CYP1B1 rs10012 G/C All AMBER 50.8 0.99 0.92 0.023 0.85 1.1x10-4 1.01 0.81 
   BWHS/WCHS/CBCS 51.2 0.99 0.93 0.062 0.85 4.8x10-4 1.02 0.77 
   MEC 49.2 0.98 0.90 0.18 0.86 0.12 0.99 0.92 
   1000G AFR, EUR 57.4, 29.0        
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Gene SNP 
Reference 
/ effect 
allele 
Sample 
 Effect allele 
frequency in 
controls (%) 
Imputation 
r2a 
All cases ER+ ER- 
OR p-value OR p-value OR p-value 
SNPs Gene-Wide Significant for ER- Breast Cancer 
PGR rs11571215 T/C All AMBER 9.2 0.97 0.90 0.083 1.02 0.75 0.64 1.1x10-5 
   BWHS/WCHS/CBCS 9.2 0.98 0.86 0.029 0.96 0.63 0.66 1.1x10-4 
   MEC 9.3 0.93 1.06 0.66 1.31 0.082 0.52 0.028 
   1000G AFR, EUR 12.0, 0.0        
            
 rs11571247 T/C All AMBER 11.7 0.99 0.94 0.29 1.08 0.24 0.69 4.8x10-5 
   BWHS/WCHS/CBCS 11.9 1.00 0.90 0.086 1.02 0.79 0.68 8.1x10-5 
   MEC 11.3 0.94 1.14 0.27 1.36 0.028 0.77 0.26 
   1000G AFR, EUR 14.4, 0.0        
            
 rs2124761 C/A All AMBER 17.5 0.99 0.90 0.020 0.96 0.48 0.76 1.6x10-4 
   BWHS/WCHS/CBCS 17.4 1.00 0.88 0.010 0.94 0.27 0.75 2.6x10-4 
   MEC 17.7 0.94 0.98 0.88 1.07 0.57 0.81 0.26 
   1000G AFR, EUR 21.9, 0.7        
            
MAPK3 rs78564187 G/A All AMBER 18.0 1.03 1.07 0.13 1.03 0.58 1.26 3.7x10-4 
   BWHS/WCHS/CBCS 18.0 genotyped 1.09 0.079 1.05 0.44 1.30 1.3x10-4 
   MEC 17.9 0.99 0.99 0.93 0.96 0.71 1.02 0.89 
   1000G AFR, EUR 21.0, 9.4        
            
MAP3K1 rs10075381 A/C All AMBER 8.0 1.00 0.94 0.35 1.05 0.55 0.66 1.5x10-4 
   BWHS/WCHS/CBCS 7.3 genotyped 1.00 0.99 1.07 0.46 0.76 0.021 
   MEC 10.5 0.97 0.77 0.054 0.98 0.91 0.25 2.2x10-4 
   1000G AFR, EUR 3.6, 35.6        
            
Abbreviations: OR, odds ratio (adjusted for study, age, region, DNA source, and genotype principal components); 1000G, 1000 Genomes 
Project Phase 3; AFR, African samples; EUR, European samples. 
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Odds ratios in bold font indicate the phenotype (overall, ER+, or ER- breast cancer) for which the gene was a top hit and the SNP was 
gene-wide significant.  CALM2 was a top hit for both overall and ER+ breast cancer, and the CALM2 SNP rs114416221 was gene-wide 
significant for both of these outcomes. 
a The imputation r2 quality metric computed by PLINK version 1.90 (97) (https://www.cog-genomics.org/plink2). 
b ALL AMBER N: 3663 cases (1098 ER-, 1983 ER+, 582 ER unknown), 4687 controls.      
c BWHS/WCHS/CBCS N: 3130 cases (963 ER-, 1674 ER+, 493 ER unknown), 3698 controls.      
d MEC N: 533 cases (135 ER-, 309 ER+, 89 ER unknown), 989 controls. 
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PROJECT 3 
 
A Novel TCF7L2 Type 2 Diabetes SNP Identified  
from Fine Mapping in African American Women 
 
 
 
ABSTRACT 
 SNP rs7903146 in the Wnt pathway’s TCF7L2 gene is the variant most 
significantly associated with type 2 diabetes to date, with associations observed across 
diverse populations.  We sought to determine whether variants in other Wnt pathway 
genes are also associated with this disease.  We evaluated 69 genes involved in the Wnt 
pathway, including TCF7L2, for associations with type 2 diabetes in 2632 African 
American cases and 2596 controls from the Black Women’s Health Study.  Tag SNPs for 
each gene region were genotyped on a custom Affymetrix Axiom Array, and imputation 
was performed to 1000 Genomes Phase 3 data.  Gene-based analyses were conducted 
using the adaptive rank truncated product (ARTP) statistic.  The PSMD2 gene was 
significantly associated with type 2 diabetes after correction for multiple testing 
(corrected p = 0.016), based on the nine most significant single variants in the +/- 20 kb 
region surrounding the gene, which includes nearby genes EIF4G1, ECE2, and EIF2B5.  
Association data on four of the nine variants were available from an independent sample 
of 8284 African American cases and 15,543 controls; associations were in the same 
direction, but weak and not statistically significant.  TCF7L2 was the only other gene 
associated with type 2 diabetes at nominal p <0.01 in our data.  One of the three variants 
in the best gene-based model for TCF7L2, rs114770437, was not correlated with the 
GWAS index SNP rs7903146 and may represent an independent association signal seen 
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only in African ancestry populations.  Data on this SNP were not available in the 
replication sample. 
 
INTRODUCTION 
 African American women experience a greater burden from type 2 diabetes 
compared to U.S. women of European ancestry.  Incidence in African American women 
is more than twice that in U.S. white women, with >50% of this excess rate remaining 
after adjustment for known type 2 diabetes risk factors including body mass index (BMI) 
(1).  In addition, African Americans with diabetes have poorer glycemic control (2) and 
an increased risk of diabetic complications and mortality (3) compared to whites.  Given 
these racial disparities, it is critical that more studies be conducted to investigate the 
etiology of type 2 diabetes in African American women. 
More than 75 genetic loci for type 2 diabetes have been discovered in European, 
Asian, and Mexican ancestry populations (4–8), while only three novel variants have 
been discovered in genome-wide association studies (GWAS) of African ancestry (AA) 
populations (9,10).  Attempts to replicate type 2 diabetes associations from European 
samples in AA populations suggest that a majority of the variants show associations in 
the same direction in AA samples (9,11–14).  However, only a few loci have achieved 
statistical significance in replication attempts.  Most notable is SNP rs7903146 in the 
TCF7L2 gene, the variant most significantly associated with type 2 diabetes to date. 
TCF7L2 encodes a transcription factor that plays an important role in the Wnt 
signaling pathway, and its risk alleles appear to be associated with impaired insulin 
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secretion / beta-cell function (15,16).  The Wnt pathway is one of the cell’s most 
important developmental and growth regulatory mechanisms (17), critical in determining 
cell fate, proliferation, polarity, and cell death during embryonic development, and also in 
adult tissue homeostasis.  Abnormalities in Wnt signaling have been implicated in a 
variety of human diseases (18). 
The Wnt signaling pathway is actually a group of signal transduction pathways:  
the canonical Wnt pathway leads to the regulation of gene transcription, and multiple 
non-canonical Wnt pathways regulate the cell’s cytoskeleton and calcium stores (18).  All 
Wnt signaling pathways are initiated by the binding of a Wnt ligand to a Frizzled family 
transmembrane receptor.  In the case of the canonical pathway, the resulting intracellular 
signaling cascade leads to the inactivation of a β-catenin destruction complex (19).  β-
catenin thus avoids destruction and translocates from the cytoplasm to the nucleus where 
it interacts with TCF7L2 and other transcription factors, replacing transcriptional 
repressors and recruiting coactivators (18,20). 
Genes involved in the β-catenin destruction complex may influence susceptibility 
to type 2 diabetes, given the critical role this complex plays in Wnt signal transduction 
with the resulting downstream effects on diabetes locus TCF7L2.  AA as well as 
European individuals may be affected, considering that the TCF7L2 / diabetes association 
is seen across racial groups.  Under one scenario, gene mutations might render the β-
catenin destruction complex inactive at all times.  In this situation, β-catenin would avoid 
destruction even in the absence of Wnt ligands, thereby accumulating in the cytoplasm 
and nucleus and binding to TCF7L2 and other transcription factors.  These transcription 
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factors would then act mostly as transcriptional activators, and overexpression of some of 
their target genes may lead to diabetes pathology.  With this type of scenario in mind, the 
present study was initiated to investigate genes involved in the β-catenin destruction 
complex for evidence of variants that may impact risk of type 2 diabetes in AA women.  
Given the small effect sizes generally seen for common susceptibility variants, the 
present analyses utilized gene-based testing in an attempt to identify important genes with 
multiple risk variants that might otherwise be missed in a SNP-based approach. 
 
METHODS 
Study Population 
The data source for the current analyses was the Black Women’s Health Study 
(BWHS) (21), a prospective cohort study of health and illness among U.S. black women 
that began in 1995 when 59,000 African American women 21-69 years of age from 
across the U.S. completed a 14-page postal health questionnaire.  Biennial follow-up 
questionnaires ascertain new cases of type 2 diabetes and other health outcomes and 
update covariate data.  Through 2013, follow-up had been completed for 88% of the 
potential years of follow-up for the baseline cohort.  The BWHS was granted approval by 
the Institutional Review Board of Boston University, and all study subjects provided 
informed consent. 
The accuracy of self-reported diabetes in the BWHS was previously assessed in a 
sample of 229 women who reported an incident diagnosis, signed a release for their 
physician to be contacted, and whose physician returned a questionnaire about diagnostic 
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criteria (22).  Based on these physician-completed questionnaires, 96% of the cases were 
confirmed.  The prevalence of undiagnosed diabetes in the BWHS was also previously 
assessed (23), using data from collected blood samples.  Of the 1873 cohort members 
who provided a blood sample in the first year of blood collection and had never reported 
diabetes, 120 (6.4%) had HbA1c levels of 6.5% (47.5 mmol/mol) or higher, meeting 
criteria for diabetes (24). 
About 50% of BWHS study participants provided DNA samples for analysis, and 
these subjects were found to be highly representative of all BWHS participants across a 
number of factors including geographic region, education, and BMI.  A case-control 
sample was drawn from among participants with DNA samples for genotyping and 
analysis: incident cases of type 2 diabetes were selected, and one control was matched to 
each case on birth year (+/- 2 years) and geographic region of residence.  
We sought replication of the top associations from the BWHS in up to 8284 
African American cases and 15,543 controls from the MEDIA (Meta-analysis of type 2 
diabetes in African Americans) Consortium, which has been previously described (10).  
MEDIA includes 17 African American type 2 diabetes GWAS. 
 
SNP Selection for Genotyping 
 The Reactome database (25,26) (http://www.reactome.org/) was used to identify 
68 genes that code for proteins involved in the Wnt pathway’s β-catenin destruction 
complex.  Tag SNPs were then selected for each of these 68 genes (+/- 20 kb from the 5’ 
and 3’ ends of the gene) in order to capture (at r2 ≥ 0.9) all SNPs with minor allele 
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frequency (MAF) ≥ 5%, based on the African populations in 1000 Genomes (27) 
(http://www.1000genomes.org/).  In addition, tag SNPs were selected for the +/- 100 kb 
region surrounding the GWAS-identified SNP rs7903146, which is located in an intron of 
gene TCF7L2.   
 
Genotyping and QC 
 Genotyping of the selected Wnt pathway SNPs was performed in two batches 
totaling 6080 samples (including duplicates), as part of a custom Affymetrix Axiom array 
that contained 45,747 SNPs chosen for several type 2 diabetes projects.  The Axiom array 
data underwent extensive QC procedures carried out by Affymetrix and Slone 
Epidemiology Center.  About 13% of samples were removed due to high missing call 
rates (defined as >5%), poor reproducibility, or Dish-QC values <0.6.  About 17% of 
SNPs were removed due to poor cluster properties, high missing call rates (defined as 
>10%), deviation from Hardy-Weinberg equilibrium (p <10-5 in controls), or high rates of 
discordant calls across duplicate samples.  Only SNPs that passed QC in both sample 
batches were retained for analyses.  After the application of these QC filters and the 
consolidation of 63 expected and confirmed duplicate sample pairs, the full type 2 
diabetes data set contained 5228 subjects (2632 cases and 2596 controls) and 38,008 
SNPs, including 3430 SNPs selected for the current analyses of Wnt pathway genes. 
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Imputation 
After prephasing the study data with SHAPEIT version 2 (28), imputation was 
performed using the IMPUTE2 software (29) and the 1000 Genomes Phase 3 multi-
ethnic reference panel (5/2/2013 1000 Genomes data, October 2014 haplotype release).  
Imputation resulted in a total of 32,165 Wnt pathway SNPs with MAF ≥ 0.5% and 
imputation info score ≥ 0.5 for analysis.  The imputation info score used for SNP filtering 
was the imputation metric produced by IMPUTE2 (30). 
 
Association Analysis 
We computed genotype principal components using the smartpca program in the 
EIGENSOFT package (31), based on 18,825 genotyped and pruned common (MAF 
>5%) SNPs in the full type 2 diabetes data set.  The principal components of genotype 
were tested for association with case status after accounting for the study covariates: age 
at baseline, geographical region, and genotyping batch.  For all association analyses, we 
included principal components that had p <0.1 in this multivariable model. 
Gene-based association analyses were conducted using the adaptive rank 
truncated product (ARTP) statistic (32), as implemented in the R package ARTP2 (33).  
The ARTP method was selected for its ability to optimize the number of single SNP p-
values combined in each gene-based test.  According to the options we set, the ARTP2 
program selected the best model (i.e. the optimal test) for each gene using between one 
and 10 SNPs per gene.  All genotyped and imputed Wnt pathway SNPs were input into 
ARTP2 for analysis.  Based on the program parameters chosen, ARTP2 removed 10,445 
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SNPs with MAF <2% in order to eliminate low frequency, imputed SNPs.  Next, it 
identified pairs of SNPs with linkage disequilibrium (LD) r2 >0.8 within each gene and 
removed the SNP with the lower MAF from each pair, resulting in removal of 14,918 
SNPs.  After implementation of the MAF and LD filters, 6802 SNPs remained for gene-
based analysis. 
Single SNP association tests, required as input for gene-based testing, were 
performed using logistic regression analyses of the imputed dosage genotype data.  All 
statistical models were adjusted for age at baseline, geographical region, genotyping 
batch, and genotype principal components. 
 
RESULTS 
 The results of the gene-based analyses are shown in Table 3.1.  One gene, 
PSMD2, was significantly associated with the risk of type 2 diabetes after a Bonferroni 
correction for the 69 genes tested (nominal p = 2.2 x 10-4, corrected p = 0.016).  One 
other gene, GWAS locus TCF7L2, was associated with a nominal p <0.01 (p = 1.5 x 10-
3). 
 Table 3.2 shows the genetic variants that were included in the best gene-based 
models selected for genes PSMD2 and TCF7L2.  The best model selected for the PSMD2 
region included nine genetic variants.  The best model selected for TCF7L2 included 
three genetic variants.  The most significantly associated variant in the TCF7L2 region 
was the GWAS index SNP rs7903146 (p = 1.0 x 10-5), which was associated with a ~20% 
increased risk of type 2 diabetes (OR 1.21, 95% CI 1.11, 1.32). 
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 Although we had removed correlated SNPs prior to gene-based testing, the r2 
threshold used was 0.8, and there was moderate LD (0.45 < r2 < 0.8) in the study sample 
among five of the top six variants in the best model for PSMD2.  Nevertheless, the nine 
variants included in the best model for PSMD2 comprised four distinct LD groups, using 
r2 = 0.35 as the cutoff for LD grouping.  For TCF7L2, there was moderate LD between 
the top two variants in the best model (rs7903146 and rs34872471 had r2 = 0.77), but 
rs114770437 was not correlated (r2 <0.05 with each of the top two SNPs). 
We next reviewed SNPs in the PSMD2 and TCF7L2 regions that had been 
removed by ARTP2 during pruning, in case any of the excluded SNPs were of interest 
due to potential functionality.  In the +/- 20 kb region surrounding PSMD2, a genotyped 
missense SNP rs2178403 (A/G, Met/Val), located in gene EIF4G1 and excluded from 
gene-based analyses due to its high LD (r2 = 0.93) with SNP rs1879244 (Table 3.2), was 
associated with diabetes risk, with a p-value smaller than that of the nine SNPs from the 
best model (p = 8.0 x 10-5).  The A allele of rs2178403 had a frequency of 6.6% in the 
study controls and was associated with a 30% decreased risk of type 2 diabetes (OR 0.70, 
95% CI 0.58, 0.83). 
Given that the most significant SNP in the PSMD2 region was potentially 
functional and the top SNP in TCF7L2 was the GWAS index SNP, we assessed how 
much of the association signal in each region was driven by these top SNPs.  We reran 
single variant analyses in these two regions, conditioning on those SNPs.  The results of 
the conditional analyses are shown in Table 3.3.  When we conditioned on rs2178403, 
three of the nine variants in the best model for PSMD2 remained nominally significant (p 
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<0.05).  When we conditioned on rs7903146, SNP rs114770437 in TCF7L2 remained 
nominally significant (p = 1.3 x 10-3).  Thus, both regions may contain multiple 
independent signals.   
A haplotype analysis of rs7903146 and rs114770437 in TCF7L2 showed the 
presence of only three of the four possible haplotypes including common haplotype 
rs7903146-C / rs114770437-G (63%), and haplotypes T/G (30%) and C/A (7%).  An 
omnibus test assessing the joint effect of all haplotypes on the risk of type 2 diabetes was 
significant with p = 2.5 x 10-7.  Compared to the C/G haplotype, the T/G haplotype was 
associated with an 18% increased risk of type 2 diabetes (OR 1.18, 95% CI 1.09, 1.29), 
and the C/A haplotype was associated with a 23% reduction in risk (OR 0.77, 95% CI 
0.66, 0.90) (Table 3.4). 
 We sought replication in the MEDIA Consortium for the top SNPs in the PSMD2 
region and for the potentially novel risk variant rs114770437 in TCF7L2.  Replication 
data were not available for rs114770437, but data were available for four of the nine 
variants in the best model for PSMD2 (rs939317, rs9846954, rs2376524, and rs1687230).  
In MEDIA, these four variants had effect estimates pointing in the same direction as 
BWHS, but the odds ratios were quite small (≤ 1.08 for the risk alleles), and none of the 
associations were statistically significant (p >0.05).  Results of a meta-analysis 
combining BWHS and MEDIA for these four SNPs are shown in Supplementary Table 
3.S1. 
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DISCUSSION 
Gene-based analyses of common variants in the vicinity of β-catenin destruction 
complex genes identified an association between the PSMD2 gene region and type 2 
diabetes in 2632 AA cases and 2596 AA controls.  Eight of the nine variants in the best 
model for PSMD2 were not located within PSMD2 itself but were instead located within 
other surrounding genes on chromosome 3q27.l (EIF4G1, ECE2, and EIF2B5) (Table 
3.2).  The most significant variant in the PSMD2 region, missense SNP rs2178403, is 
located within a plausible diabetes candidate gene, EIF4G1.  EIF4G1 encodes a 
component of the multi-subunit protein complex EIF4F.  The EIF4F complex facilitates 
recruitment of mRNA to the ribosome, which is the rate-limiting step in protein 
synthesis.  There is evidence that compromised insulin signaling in pancreatic beta cells 
downregulates EIF4G1, leading to the inhibition of carboxypeptidase E (CPE) 
expression, with a subsequent reduction of proinsulin processing and a corresponding 
increase in the levels of circulating proinsulin (34). 
 While EIF4G1 is a potential susceptibility gene, the results of our analyses 
conditioning on rs2178403 suggest that the association signal in the PSMD2 region, if 
valid, may not be fully captured by variants in EIF4G1 alone.  Furthermore, other genes 
in this region, including PSMD2 itself, could be linked to diabetes pathology.  The 
PSMD2 gene was included in this study because of its involvement in the Wnt pathway’s 
β-catenin destruction complex: PSMD2 encodes a regulatory subunit of the 26S 
proteasome, and it is the 26S proteasome that carries out the actual destruction of β-
catenin (as well as other ubiquitinated proteins) (35,36).  It has been shown that a high fat 
110 
	
	
diet downregulates hepatic transcription of PSMD2 in mice that are resistant to the 
development of insulin resistance and non-alcoholic fatty liver disease (NAFLD), while 
upregulating transcription in mice with susceptibility to developing insulin resistance and 
NAFLD (37).   
 ECE2 is another possible susceptibility gene near PSMD2.  The enzyme encoded 
by ECE2 converts big endothelin-1 to the vasoconstrictor endothelin-1, and is involved in 
the processing of several neuroendocrine peptides.  This enzyme may also act as a 
methyltransferase.  A mouse study reported an association between hyperglycemia at an 
early stage of autoimmune diabetes and downregulation of ECE2 transcription in the 
kidneys (38).  In our study, the most significant variant in the top model for the PSMD2 
region, rs55808452, was located within an intron of ECE2, although it should be noted 
that this variant was in moderate LD with several EIF4G1 variants including missense 
SNP rs2178403 (r2 = 0.54). 
It is unclear whether the association we observed with the PSMD2 region is a true 
finding or a false positive result.  Associations for four of the top variants in this region 
failed to replicate in the large AA sample from the MEDIA Consortium.  Although the 
odds ratios for these four variants were close to the null (0.92-0.98) in MEDIA, they were 
in the same direction as our study.  Thus, it is possible that these variants are truly 
associated but have very small effects (as estimated in the larger MEDIA sample), 
limiting power to achieve statistical significance.  Another consideration is that the 
MEDIA analysis included both men and women, whereas our analysis included only 
women.  A stronger effect for these variants in AA women compared to AA men might 
111 
	
	
explain the failed replication.  The other five variants in the best model for PSMD2 were 
not available in MEDIA.  While four of these five variants were in moderate LD (r2 >0.7) 
with at least one of the SNPs that failed replication, their linkage disequilibrium r2 values 
with the failed SNPs were <0.8 due to the pruning process we performed.  Therefore, we 
cannot rule out the presence of a true association with one or more of these five.  
Although none of the variants from the best PSMD2 model were significantly associated 
with type 2 diabetes in prior meta-analyses of GWAS that included very large samples of 
European ancestry subjects as well as subjects of Asian and Mexican ancestry (5,7), this 
could reflect a (relatively) larger role for these variants in AA vs. European ancestry 
populations.  For instance, a certain environmental or genetic background more prevalent 
in AA subjects may be required for genetic variants in this region to impact disease 
susceptibility.  Also, due to differential LD patterns, the assayed variants may do a better 
job of tagging a given causal variant in AA vs. European populations, and a tagged causal 
variant might also be more common or exclusively seen in AA samples. 
Apart from the PSMD2 region, the other interesting finding from the present 
study concerned the GWAS gene TCF7L2.  SNP rs114770437 was one of three variants 
included in the best gene-based model for TCF7L2 and was not correlated with the 
GWAS index SNP rs7903146.  The A allele at rs114770437 had a frequency of 7.8% in 
the study controls and was associated with a 27% reduction in the risk of type 2 diabetes.  
The association with this SNP remained nominally significant after control for rs7903146 
(conditional OR = 0.77; p = 1.3 x 10-3).  Thus, rs114770437 may represent an 
independent association signal in TCF7L2 in AA populations.  SNP rs114770437 is 
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monomorphic in 1000 Genomes European samples, and this may explain the results of a 
Bayesian fine mapping analysis by the Wellcome Trust Case Control Consortium 
(WTCCC), which suggested that no such secondary signal exists in TCF7L2 in 
Europeans (39).  In the WTCCC study, the posterior probability that rs7903146 was 
driving the TCF7L2 association signal was 75%.  An additional 13% of the posterior 
probability was accounted for by correlated SNP rs34872471, the second most significant 
SNP in the best model for TCF7L2 in our study.  No other SNP accounted for more than 
3% of the posterior probability.   
Despite a respectable sample size of 2632 AA cases and 2596 AA controls, the 
present study had limited power to detect individual SNP associations.  Another 
limitation was the use of imputed genotypes for many SNPs.  However, SNPs with an 
imputation info score <0.5 or MAF <2% were excluded from the association analyses in 
order to improve the accuracy of the data used.  Lastly, non-differential misclassification 
of diabetes in our sample, though likely to be small, may have resulted in underestimation 
of the associations. 
 In summary, we observed a significant association between the PSMD2 gene 
region and type 2 diabetes in women of African ancestry in a gene-based analysis.  This 
finding opens the possibility that PSMD2, a gene involved in the Wnt pathway’s β-
catenin destruction complex, or another nearby gene such as EIF4G1 or ECE2, may be a 
susceptibility locus for type 2 diabetes.  It is also possible that the observed association is 
a false positive result, given the failed replication of a subset of the top SNPs in this 
region.  Our analyses also suggested a possible association signal in TCF7L2 that is 
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independent of the GWAS index SNP rs7903146 and may be present only in AA 
populations.  Replication is needed in additional AA samples in order to validate our 
findings. 
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Table 3.1:  Associations of Wnt pathway genes with risk of type 2 diabetes in the BWHS. 
Gene Chromosome Number of SNPs in the analysis P-value 
PSMD2a 3 51 2.2 x 10-4 
TCF7L2 10 368 1.5 x 10-3 
PSMD11 17 53 0.017 
CSNK1A1 5 104 0.025 
FRAT1 10 62 0.033 
PSME2 14 68 0.042 
PSME1 14 59 0.051 
PSMD4 1 40 0.095 
PSMD14 2 49 0.11 
PSMB1 6 67 0.12 
PSMD12 17 86 0.15 
PPP2R5D 6 85 0.15 
PSMD10 23 11 0.15 
PSME4 2 148 0.15 
UBC 12 154 0.17 
PSMC1 14 97 0.17 
UBA52 19 96 0.18 
FRAT2 10 62 0.19 
PSMB10 16 33 0.19 
CTNNB1 3 123 0.22 
PPP2R1B 11 74 0.23 
APC 5 183 0.23 
PPP2R5C 14 375 0.26 
PSMB6 17 105 0.27 
PSMB3 17 128 0.28 
PSMA2 7 53 0.30 
PPP2R5E 14 381 0.30 
PSMD3 17 121 0.31 
PPP2R1A 19 144 0.32 
PSMC2 7 65 0.33 
PSMB8 6 135 0.35 
PSMB9 6 141 0.36 
GSK3B 3 182 0.37 
BTRC 10 110 0.37 
UBB 17 64 0.39 
PSMD6 3 103 0.40 
PSMA6 14 88 0.40 
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Gene Chromosome Number of SNPs in the analysis P-value 
PSMC5 17 29 0.40 
PSMD5 9 51 0.40 
AMER1 23 14 0.40 
PSMA8 18 90 0.40 
PSMA7 20 65 0.41 
PSMD13 11 189 0.42 
PSMD1 2 121 0.42 
PSMC3 11 58 0.51 
PPP2CB 8 109 0.55 
RPS27A 2 35 0.57 
PSMA3 14 48 0.60 
PSMB4 1 51 0.61 
PSMA5 1 31 0.64 
PSMC4 19 42 0.67 
PSMD8 19 62 0.68 
PSMC6 14 77 0.75 
CUL1 7 218 0.81 
PSMA1 11 95 0.83 
PSMD7 16 46 0.83 
PSMA4 15 61 0.83 
PSMF1 20 194 0.84 
PSMB2 1 77 0.86 
PPP2R5A 1 81 0.87 
AXIN1 16 378 0.89 
PPP2R5B 11 59 0.90 
PPP2CA 5 60 0.91 
PSMB5 14 120 0.96 
PSME3 17 40 0.96 
PSMB11 14 107 0.96 
SKP1 5 83 0.96 
PSMD9 12 61 0.97 
PSMB7 9 134 0.99 
a Gene PSMD2 remains significant after a Bonferroni correction for the 69 genes tested (corrected p = 
0.016). 
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Table 3.2:  Genetic variants comprising the optimal models for PSMD2 and TCF7L2: associations with risk of type 2 diabetes. 
Variant Genea Reference  allele 
Minor 
allele 
Minor allele frequency (%): Imputation 
r2b OR (95% CI) P-value BWHS AFR EUR 
PSMD2 region 
rs55808452 ECE2 GGCAAAGGGTGG - 13.0 NA NA 0.70 0.75 (0.65, 0.87) 1.0 x 10-4 
rs7635741 EIF4G1 G T 8.1 3.5 22.8 0.61 0.69 (0.56, 0.84) 2.2 x 10-4 
rs1879244 EIF4G1 T C 7.1 1.7 24.7 0.95 0.72 (0.60, 0.86) 2.4 x 10-4 
rs939317 EIF4G1 G A 9.0 4.1 24.7 genotyped 0.76 (0.65, 0.88) 2.6 x 10-4 
rs9846954 EIF4G1 T A 48.8 42.0 75.1 genotyped 0.87 (0.80, 0.94) 4.2 x 10-4 
rs2376524 EIF2B5 A C 7.6 2.7 23.2 0.93 0.75 (0.63, 0.88) 5.8 x 10-4 
rs9883929 PSMD2 A C 18.2 22.4 8.0 0.91 1.19 (1.07, 1.32) 9.6 x 10-4 
rs1687230 ECE2 T C 16.5 11.1 37.0 genotyped 0.84 (0.75, 0.94) 2.2 x 10-3 
rs72591978 EIF2B5 CA C 46.5 NA NA 1.01 0.89 (0.82, 0.96) 2.9 x 10-3 
          
TCF7L2 region 
rs7903146 TCF7L2 C T 28.2 26.0 31.7 genotyped 1.21 (1.11, 1.32) 1.0 x 10-5 
rs34872471 TCF7L2 T C 33.6 31.2 31.5 1.02 1.20 (1.10, 1.30) 1.6 x 10-5 
rs114770437 TCF7L2 G A 7.8 9.1 0.0 genotyped 0.73 (0.62, 0.85) 7.7 x 10-5 
          
Abbreviations: BWHS, Black Women’s Health Study controls; AFR, 1000 Genomes Project Phase 3 African samples; EUR, 1000 Genomes Project 
Phase 3 European samples; OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, and genotype principal components); 
CI, confidence interval; NA, not applicable (allele frequencies are not available in 1000 Genomes). 
a All SNPs are intronic. 
b The imputation r2 quality metric computed by PLINK version 1.90 (40) (https://www.cog-genomics.org/plink2). 
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Table 3.3:  Genetic variants comprising the optimal models for PSMD2 and TCF7L2: analyses conditioning on the top SNPs. 
Variant Reference  allele 
Minor 
allele OR P-value 
Conditional 
ORa,b 
Conditional 
p-value Comment 
PSMD2 region 
rs2178403 G A 0.70 8.0 x 10-5 NA NA excluded from gene-based  analysis during pruning 
rs55808452 GGCAAAGGGTGG - 0.75 1.0 x 10-4 0.85 0.14  
rs7635741 G T 0.69 2.2 x 10-4 0.92 0.71  
rs1879244 T C 0.72 2.4 x 10-4 1.19 0.60  
rs939317 G A 0.76 2.6 x 10-4 0.90 0.40  
rs9846954 T A 0.87 4.2 x 10-4 0.90 8.6 x 10-3  
rs2376524 A C 0.75 5.8 x 10-4 1.00 0.98  
rs9883929 A C 1.19 9.6 x 10-4 1.17 3.3 x 10-3  
rs1687230 T C 0.84 2.2 x 10-3 0.91 0.16  
rs72591978 CA C 0.89 2.9 x 10-3 0.92 0.039  
        
TCF7L2 region 
rs7903146 C T 1.21 1.0 x 10-5 NA NA  
rs34872471 T C 1.20 1.6 x 10-5 1.08 0.36  
rs114770437 G A 0.73 7.7 x 10-5 0.77 1.3 x 10-3  
        
Abbreviations: OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, genotype principal components); NA, not applicable. 
a Conditional odds ratios for variants in the PSMD2 region are adjusted for age at baseline, geographical region, genotyping batch, genotype principal 
components, and SNP rs2178403.   
b Conditional odds ratios for variants in the TCF7L2 region are adjusted for age at baseline, geographical region, genotyping batch, genotype principal 
components, and SNP rs7903146. 
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Table 3.4:  Haplotype analysis of SNPs rs7903146 and rs114770437 in TCF7L2. 
rs7903146 allele rs114770437 allele 
Haplotype frequency (%) 
OR (95% CI) P-value 
Cases (n = 2632) Controls (n = 2596) 
C G 62.3 64.1 1.00 (reference) reference 
T G 31.7 28.1 1.18 (1.09, 1.29) 5.7 x 10-5 
C A 6.0 7.8 0.77 (0.66, 0.90) 1.3 x 10-3 
Abbreviations: OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, and genotype principal components); 
CI, confidence interval. 
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Supplementary Table 3.S1:  Meta-analysis of BWHS and MEDIA for the PSMD2 region. 
SNP 
BWHS  MEDIA  BWHS + MEDIA 
OR (95% CI) P-value  OR (95% CI) P-value  OR (95% CI) P-value 
rs939317 0.76 (0.65, 0.88) 2.6 x 10-4  0.94 (0.84, 1.04) 0.23  0.87 (0.80, 0.95) 1.9 x 10-3 
rs9846954 0.87 (0.80, 0.94) 4.2 x 10-4  0.97 (0.92, 1.02) 0.26  0.94 (0.90, 0.98) 4.1 x 10-3 
rs2376524 0.75 (0.63, 0.88) 5.8 x 10-4  0.92 (0.82, 1.04) 0.18  0.86 (0.78, 0.95) 2.1 x 10-3 
rs1687230 0.84 (0.75, 0.94) 2.2 x 10-3  0.98 (0.92, 1.04) 0.48  0.94 (0.89, 1.00) 0.033 
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CONCLUSION 
 The projects conducted here explored the etiology of breast cancer and type 2 
diabetes in women of African ancestry, using pathway- and gene-based analysis methods.  
Project 1 evaluated rare variants across the exome and found that PDE4D (previously 
identified in GWAS) and FBXL22 (a novel gene) were associated with ER- (and triple 
negative) breast cancer based on very small counts at extremely rare SNPs (two missense 
SNPs in each gene).  Project 2 evaluated genes in hormone-related pathways and 
identified eight genes that contained common variants associated with breast cancer in 
AA women after gene-level correction for multiple testing, including the PGR gene for 
ER- cancer.  Project 3 evaluated genes involved in the Wnt pathway’s β-catenin 
destruction complex and identified an association between the PSMD2 gene region and 
type 2 diabetes, although a subset of the top PSMD2 SNPs were available and failed to 
replicate in the large AA sample from the MEDIA Consortium.  Project 3 also found 
suggestive evidence for a novel TCF7L2 type 2 diabetes SNP that may represent an 
independent association signal seen only in AA populations. 
 Our pathway- and gene-based analytic approaches provided greater power for 
discovery compared to single SNP analyses.  Single SNP analyses yielded only one 
statistically significant result across the three projects: an association between the 
previously discovered GWAS SNP rs8100241 and ER- breast cancer.  This association is 
of limited interest because the primary goal of the current projects was the discovery of 
novel risk variants.  It is true that some of our findings from gene-based analysis may be 
false positive associations; however, other findings may be real and made possible 
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through the increase in statistical power afforded by the gene-based approach. 
 The importance of studying an AA population is also apparent in our results.  Ten 
of the 12 SNPs of interest located in hormone pathway genes in Project 2 had lower allele 
frequencies in 1000 Genomes European vs. African ancestry samples.  Furthermore, five 
of these 12 SNPs had 1000 Genomes European allele frequencies <1%, including SNPs 
in CALM2, NR0B1, and PGR (the top genes for overall, ER+, and ER- breast cancer, 
respectively, in Project 2).  In addition, the most significant SNP in the PGR gene was 
monomorphic in 1000 Genomes Europeans.  One of the primary findings from Project 3, 
a potentially novel TCF7L2 type 2 diabetes SNP, was also monomorphic in 1000 
Genomes European samples.  Identification of associations with variants found more 
commonly or exclusively in African vs. European ancestry populations suggests the 
presence of AA-specific genetic risk factors for breast cancer and type 2 diabetes and 
explains why some of the associations we observed may not have been found previously 
in large European GWAS.  AA-specific genetic risk factors may explain some portion of 
the excess disease burden experienced by AA women compared to their white 
counterparts. 
 The findings reported here are not definitive and do not allow for confirmation or 
rejection of the general hypotheses tested in each project.  Replication of the specific 
associations we observed is required using independent AA samples.  Future studies 
should also consider the entire gene regions we identified and not focus solely on the 
specific variants highlighted.  Sequencing and the use of genotyping arrays designed to 
capture AA-specific variants may uncover novel associations in these same genes with 
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rare variants that were not previously assayed.  Additional validated associations in AA 
women may shed light on the racial disparities seen for breast cancer and type 2 diabetes 
and may provide more insight into the pathophysiology of these diseases – important 
steps toward the ultimate goal of improving disease prevention, diagnosis, and treatment. 
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